{"text": "Statistical Analyses .Improvement from baseline in ADHD - RS - IV total score to week 5 was evaluated by using analysis of covariance with terms for baseline ADHD - RS - IV score , study site , and treatment group .", "label": "", "metadata": {}, "score": "41.766556"}
{"text": "Along with longstanding associations of cigarette smoking in ADHD [ 14 , 15 ] , recent work has shown the efficacy of nicotine and nicotinic analogs in the treatment of ADHD [ 16 , 17 ] .", "label": "", "metadata": {}, "score": "42.928368"}
{"text": "Negative correlations indicate that patients with high ADHD - RS scores have low CHIP - CE scores and vice versa .Overall , correlations were in the small to medium range , showing a consistent trend toward stronger correlations at endpoint and in change from baseline , compared with the baseline correlations .", "label": "", "metadata": {}, "score": "43.705074"}
{"text": "Specifically , the correlations between the ADHD - RS scores ( both sub - scores and total score ) and the Risk Avoidance domain and sub - domains were smaller in adolescents with regard to change from baseline .", "label": "", "metadata": {}, "score": "44.607277"}
{"text": "Study Assessments .The primary efficacy measure was improvement from baseline to week 5 in ADHD - RS - IV total score versus placebo using a last observation carried forward ( LOCF ) method .", "label": "", "metadata": {}, "score": "45.33625"}
{"text": "Efficacy Outcome Measures .The primary efficacy outcome was the change in mean ADHD - RS - IV total score from baseline to treatment endpoint , defined as the last postrandomization week for which a score was obtained .", "label": "", "metadata": {}, "score": "45.765724"}
{"text": "This could be due to the composition of samples in clinical trials as opposed to epidemiological samples .Analyzing the ADHD - RS in the present post - hoc analysis , children had significantly higher hyperactive / impulsive sub - scores and total scores compared with adolescents at baseline .", "label": "", "metadata": {}, "score": "46.206684"}
{"text": "METHODS .Patient Population .ADHD was evaluated by using the Kiddie - Sads - Present and Lifetime Version questionnaire 1.0 completed by a trained investigator .", "label": "", "metadata": {}, "score": "46.2986"}
{"text": "Statistical Analyses .ADHD - RS - IV total and CPRS - R ADHD Index scores were summarized as mean ( standard deviation [ SD ] ) .", "label": "", "metadata": {}, "score": "46.73573"}
{"text": "Correlations between ADHD - RS and CHIP - CE scores were generally low at baseline and moderate in change from baseline and were overall similar in adolescents and children .", "label": "", "metadata": {}, "score": "46.824574"}
{"text": "The 4-week study duration limits the ability to extrapolate the findings to the long - term treatment generally required in managing ADHD .This study was not prospectively designed or powered to detect differences between the treatment groups .", "label": "", "metadata": {}, "score": "46.939636"}
{"text": "Milberger S , Biederman J , Faraone S , Chen L , Jones J : ADHD is associated with early initiation of cigarette smoking in children and adolescents .", "label": "", "metadata": {}, "score": "47.42801"}
{"text": "In addition , a statistical analysis on potential predictors of change in CAARS : O - SV score on all time points per patient during treatment was performed using a mixed model .", "label": "", "metadata": {}, "score": "47.58924"}
{"text": "Such differences in terms of cultural diversity could have had an impact on the evaluation both of core symptoms as measured with the ADHD - RS , and health - related quality of life as measured with the CHIP - CE .", "label": "", "metadata": {}, "score": "47.695587"}
{"text": "Similarly , there were no significant differences in anxiety score between groups over the 8-week study period ( Mean - A. Computerized Cognitive Assessments .", "label": "", "metadata": {}, "score": "47.934235"}
{"text": "ADHD - RS - IV total and CPRS - R ADHD Index scores were summarized as mean ( SD ) .Dunnett test was used to compare change from baseline in all groups .", "label": "", "metadata": {}, "score": "48.096855"}
{"text": "The ADHD - RS - IV is a standardized , validated test for assessing symptoms of ADHD and for assessing their response to treatment .The analysis also studied duration of effect using the Conners ' Parent Rating Scale - Revised Short Form ( CPRS - R ) , which is a comprehensive scale that used observer and self - report ratings to help assess ADHD and evaluate behavioral issues in children and adolescents .", "label": "", "metadata": {}, "score": "48.16684"}
{"text": "Using the change in the ADHD - RS - IV total score from baseline to endpoint as the primary efficacy measure , responders were defined as those with a 25 percent reduction in score from baseline to endpoint .", "label": "", "metadata": {}, "score": "48.43981"}
{"text": "Figure \u200b Figure2 2 and \u200b and3 3 show the correlation between ADHD - RS total score and CHIP - CE , by age group .", "label": "", "metadata": {}, "score": "48.537056"}
{"text": "The analysis was based on a repeated measures ANOVA model taking account intrasubject correlation of scores over the 6 study visits .The best choice of model was a linear spatial correlation assumption .", "label": "", "metadata": {}, "score": "49.570038"}
{"text": "A random effect of subjects - within - treatment was fitted to the model .Planned comparisons were conducted between the two treatments at each post - dosing time .", "label": "", "metadata": {}, "score": "49.667953"}
{"text": "Treatment - group differences were compared using a fixed effect analysis of covariance ( ANCOVA ) model including the terms treatment , study , age group , baseline ADHD - RS score , and the respective baseline CHIP - CE score .", "label": "", "metadata": {}, "score": "49.983406"}
{"text": "2.3.1 Sample Size Calculation .The use of a 30 % reduction in ADHD symptoms is more conservative than recent trials ( 25 % reduction ; [ 26 ] ) and commensurate with previous work [ 17 , 28 , 29 ] .", "label": "", "metadata": {}, "score": "50.004807"}
{"text": "Objectives .To explore the influence of age on treatment responses to atomoxetine and to assess the relationship between core symptoms of attention deficit / hyperactivity disorder ( ADHD ) and health - related quality of life ( HR - QoL ) outcomes .", "label": "", "metadata": {}, "score": "50.103355"}
{"text": "The baseline variables Sex ( F , M ) , history of Alcohol ( Y , N ) , Smoker ( Y , N , former ) , Age and Weight were included .", "label": "", "metadata": {}, "score": "50.52543"}
{"text": "Changes in ADHD - RS - IV Total Scores .Mean ( SD ) screening , baseline , and endpoint ADHD - RS - IV total scores for nonremitters during prior MPH treatment , nonremitters stratified according to prior MPH dosage received , and overall efficacy population are shown in Figure 1 .", "label": "", "metadata": {}, "score": "51.120552"}
{"text": "Improvement in ADHD - RS - IV total score from baseline to week 5 in CLON - XR and placebo combined with different classes of stimulants .", "label": "", "metadata": {}, "score": "51.136467"}
{"text": "Because of the nature of the study , a homogenous study population was selected that may not generalize to typical adults with ADHD .For example , subjects with significant medical histories and psychiatric co - morbidities were excluded .", "label": "", "metadata": {}, "score": "51.344673"}
{"text": "Finally , the meta - analysis included patient reported HR - QoL outcomes as a secondary endpoint .Thus , the analysis can be considered an important contribution to the body of data on the relationship between outcomes in terms of ADHD core symptoms and HR - QoL outcomes based on closely monitored clinical trials rather than cross - sectional ( or observational ) studies .", "label": "", "metadata": {}, "score": "51.47056"}
{"text": "Improvement in ADHD - RS - IV total score from baseline .Improvement was significantly greater in the CLON - XR plus stimulant group versus the placebo plus stimulant group starting at week 2 and continuing through week 7 .", "label": "", "metadata": {}, "score": "51.505974"}
{"text": "Results .ADHD - RS - IV total scores , changes from baseline , clinical responsiveness , and rates of symptomatic remission in this subgroup were comparable to the overall population .", "label": "", "metadata": {}, "score": "51.73916"}
{"text": "Symptoms of ADHD were evaluated on a weekly basis by clinicians using the ADHD Rating Scale ( ADHD - RSIV ) , which includes both hyperactive / impulsive and inattentive subscales .", "label": "", "metadata": {}, "score": "51.810577"}
{"text": "ABOUT THE STUDIES .Study SPD489 - 406 .The primary efficacy outcome was defined as the change from baseline at Week 6 ( Visit 6 ) in the ADHD - RS - IV total score .", "label": "", "metadata": {}, "score": "52.079372"}
{"text": "Colored text and dots are used for illustrational purposes .Figure 3 shows the Pearson 's correlation coefficients between the CHIP - CE change from baseline and ADHD - RS total score , by age groups based on data of all 5 trials .", "label": "", "metadata": {}, "score": "52.33558"}
{"text": "Second , drug history of the patients was mostly unknown ( with the exception of Studies 2 and 4 , where one of the inclusion criteria was that the patients had to be treatment - na\u00efve ) : this could have introduced some variability in the evaluation of treatment efficacy .", "label": "", "metadata": {}, "score": "52.349556"}
{"text": "This difference was also reflected in the ADHD - RS scores , where the hyperactive / impulsive subscore was significantly higher in children , leading to a significantly higher total score ( Table \u200b ( Table3 3 ) .", "label": "", "metadata": {}, "score": "52.622314"}
{"text": "This may explain the low to moderate correlation between ADHD core symptoms and HR - QoL in this meta - analysis .However , in order to analyze differential effects between children and adolescents in terms of factors influencing the impairment of HR - QoL , an even larger sample size would be required .", "label": "", "metadata": {}, "score": "52.90721"}
{"text": "Analyses of secondary end points were similar to those of the primary efficacy variables .Effect size was calculated on the basis of the observed mean differences between the groups and the observed SDs using the unbiased version of Hedges ' g .", "label": "", "metadata": {}, "score": "52.921234"}
{"text": "This study is the first in which CLON - XR in combination with stimulants in ADHD youth with inadequate response to stimulants is evaluated .CLON - XR plus stimulant resulted in significantly greater improvement in ADHD - RS - IV total scores at week 5 compared with placebo plus stimulant .", "label": "", "metadata": {}, "score": "52.96541"}
{"text": "Adverse events and changes in vital signs in the CLON - XR group were generally mild .CONCLUSIONS : The results of this study suggest that CLON - XR in combination with stimulants is useful in reducing ADHD in children and adolescents with partial response to stimulants .", "label": "", "metadata": {}, "score": "53.549683"}
{"text": "Conversely , just under half may have received suboptimal doses .Moreover , none of these measures differed from those observed in the overall study population .", "label": "", "metadata": {}, "score": "53.66419"}
{"text": "Group comparisons at baseline were based on two - way analysis of variance ( ANOVA ) using the terms age and study for continuous variables and based on the Cochran - Mantel - Haenszel test controlling for study in the case of categorical variables .", "label": "", "metadata": {}, "score": "53.708313"}
{"text": "In comparing children and adolescents with ADHD , this meta - analysis investigated three different aspects : the evaluation of HR - QoL at baseline , the association between HR - QoL and ADHD core symptoms , and the treatment effect of atomoxetine on HR - QoL.", "label": "", "metadata": {}, "score": "53.78633"}
{"text": "Finally , the duration of the study was relatively short .It is important for future work to characterize both the efficacy and safety of long - term combination treatment with CLON - XR and stimulants .", "label": "", "metadata": {}, "score": "53.88549"}
{"text": "Safety Assessments .Safety assessments , in enrolled participants who received at least 1 dose of study medication , have been reported previously [ 17 ] .", "label": "", "metadata": {}, "score": "54.426037"}
{"text": "The baseline correlations between the CHIP - CE and ADHD - RS scores indicated a consistent , small - to - moderate negative correlation between the core symptoms of ADHD and HR - QoL in both age groups without substantial age differences .", "label": "", "metadata": {}, "score": "54.444828"}
{"text": "Signs and symptoms of ADHD were evaluated on a once weekly basis using the clinician administered and scored ADHD Rating Scale ( ADHD - RS - IV ) , which includes both hyperactive / impulsive and inattentive subscales .", "label": "", "metadata": {}, "score": "54.496483"}
{"text": "Safety was assessed by spontaneously reported adverse events , vital signs , electrocardiogram recordings , and clinical laboratory values .Improvement from baseline for all efficacy measures was evaluated using analysis of covariance .", "label": "", "metadata": {}, "score": "54.990196"}
{"text": "This meta - analysis must be seen in the broader context of previous research on Health - Related Quality of Life ( HR - QoL ) in children and adolescents with ADHD [ 45 ] .", "label": "", "metadata": {}, "score": "54.99327"}
{"text": "Changes in cardiovascular parameters as a result of treatment with CLON - XR were consistent with known effects of the drug ( ie , decreased heart rate and blood pressure ) but were not clinically significant .", "label": "", "metadata": {}, "score": "55.177887"}
{"text": "This analysis served as a sensitivity check for the analysis on the main analysis set , as any findings from the analyses on the completers can not be attributed to ( early ) discontinuation .", "label": "", "metadata": {}, "score": "55.189255"}
{"text": "In the monotherapy trials ( Studies 1 and 2 ) , subgroup analyses were performed to identify any differences in response based on gender or age ( 6 - 12 vs. 13 - 17 ) .", "label": "", "metadata": {}, "score": "55.21084"}
{"text": "This finding is in line with several previous studies [ 15 , 18 - 25 , 48 ] .Our results indicate that adolescents might benefit more from atomoxetine treatment than children with regard to improvement in the Risk Avoidance domain and Threats to Achievement sub - domain .", "label": "", "metadata": {}, "score": "55.353996"}
{"text": "Regression analysis of variables affecting change in CAARS : O - SV score ( completer population ) .Discussion .In the present study , adherence to OROS MPH treatment was generally high , as might be expected in a randomized , placebo - controlled trial .", "label": "", "metadata": {}, "score": "55.498047"}
{"text": "Results .Participant Demographics and Disposition .Of these , 285 had a postrandomization symptom assessment and were included in the efficacy population .Full demographic data for this population have been previously reported [ 17 ] .", "label": "", "metadata": {}, "score": "55.608353"}
{"text": "The Structured Clinical Interview for DSM - IV Axis I disorders ( SCID - I ) was used to evaluate the presence of co - morbidities and to exclude other disorders .", "label": "", "metadata": {}, "score": "55.648026"}
{"text": "Overall , this meta - analysis found that , compared with children , adolescents with ADHD were somewhat more impaired at baseline , in regard to some domains of HR - QoL as measured by the CHIP - CE .", "label": "", "metadata": {}, "score": "55.762924"}
{"text": "Differences between children and adolescents in treatment response to atomoxetine and the correlation between health - related quality of life and Attention Deficit / Hyperactivity Disorder core symptoms : Meta - analysis of five atomoxetine trials .", "label": "", "metadata": {}, "score": "55.843082"}
{"text": "View Article PubMed .Kollins SH , McClernon FJ , Fuemmeler BF : Association between smoking and attention - deficit / hyperactivity disorder symptoms in a population - based sample of young adults .", "label": "", "metadata": {}, "score": "55.985714"}
{"text": "In the primary analysis [ 17 ] , Biederman et al reported on the ADHD - RS - IV ( primary outcome measure ) and CGI - I ( secondary outcome measure ) as continuous measures .", "label": "", "metadata": {}, "score": "56.1165"}
{"text": "Data from five similar clinical trials of atomoxetine in the treatment of children and adolescents with ADHD were included in this meta - analysis .Study Selection .", "label": "", "metadata": {}, "score": "56.258163"}
{"text": "However , as the hyperactivity / impulsivity issues decrease , the relative importance of the inattention problems may increase .These findings need to put into perspective .", "label": "", "metadata": {}, "score": "56.39456"}
{"text": "Overall adherence was calculated as the average daily adherence during the 13-week double - blind study .Statistical analysis .For the purposes of this post - hoc analysis , the main analysis set was defined as all randomized subjects who received at least one dose of study medication and had at least one post - baseline efficacy assessment .", "label": "", "metadata": {}, "score": "56.820423"}
{"text": "3.3 Efficacy .Investigator - rated ADHD - RS .Mean Investigator rated ADHD - RS Score ( ITT Population ) for ( a ) all Subjects , ( b ) the ADHD Inattentive Subgroup and ( c ) the ADHD Combined Subgroup .", "label": "", "metadata": {}, "score": "56.924484"}
{"text": "These studies had small sample sizes , however , and were based on patient reports of adherence , so direct comparison with the present study is difficult .", "label": "", "metadata": {}, "score": "57.074944"}
{"text": "The ADHD - RS comprises a total score , an inattentive sub - score , and a hyperactive / impulsive sub - score . 2.3 Statistical analysis .", "label": "", "metadata": {}, "score": "57.07892"}
{"text": "The aggregate data also support the concept that ADHD in adults shares many phenotypic and genotypic similarities with the childhood form of the disorder [ 9 ] .", "label": "", "metadata": {}, "score": "57.10045"}
{"text": "APA .Krause K , Dresel SH , Krause J , Kung HF , Tatsch K : Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder : effects of methylphenidate as measured by single photon emission computed tomography .", "label": "", "metadata": {}, "score": "57.12476"}
{"text": "Design , sample size , and duration of the respective studies are described in Table \u200b Table1 1 .Basic information on the 5 clinical trials included in this meta - analysis .", "label": "", "metadata": {}, "score": "57.132668"}
{"text": "In support of the latter , a relationship between doses of stimulants necessary to improve cognition ( lower ) relative to hyperactivity / impulsivity ( higher ) has been speculated [ 32 ] .", "label": "", "metadata": {}, "score": "57.23549"}
{"text": "Further evaluation of the efficacy and safety information is currently under way .Study SPD489 - 405 .The primary efficacy outcome was defined as the change from baseline at Week 8 ( Visit 8) in the Attention - Deficit / Hyperactivity Disorder Rating Scale - IV ( ADHD - RS - IV ) total score .", "label": "", "metadata": {}, "score": "57.270454"}
{"text": "When QT interval was corrected using Bazett 's formula or Fridericia 's formula , there were no clinically relevant differences between the placebo plus stimulant and CLON - XR plus stimulant groups in the number of individuals with increased QT interval ( Table 5 ) .", "label": "", "metadata": {}, "score": "57.303326"}
{"text": "Safety and tolerability evaluations of Vyvanse and Concerta included treatment - emergent adverse events ( TEAEs ) , vital signs , and weight .Exclusion criteria included a known history of cardiovascular disease , clinically significant ECG , blood pressure exceeding the 90th percentile for age , sex and height , current psychiatric diagnosis and a history of substance abuse or dependence .", "label": "", "metadata": {}, "score": "57.315727"}
{"text": "wnl.0000184517.69816 . e9 .View Article PubMed .Wilens T , Frazier J , Prince J , Spencer T , Bostic J , Hatch M , Abrantes A , Sienna M , Soriano J , Millstein R , Biederman J : A double blind comparison of pemoline in adults with ADHD : Preliminary results .", "label": "", "metadata": {}, "score": "57.399197"}
{"text": "A bimodal pattern of clinical response to atomoxetine has been described , with no obvious demographic or clinical predictors of clinical response [ 33 ] .", "label": "", "metadata": {}, "score": "57.63848"}
{"text": "As expected , baseline CAARS : O - SV score was also significantly associated with improvement in CAARS : O - SV , as was time since ADHD diagnosis .", "label": "", "metadata": {}, "score": "57.78679"}
{"text": "The CAARS : O - SV has shown very high model fit in healthy control and ADHD patient samples , and the reliability and cross - cultural validity of the instrument have been demonstrated [ 20 ] .", "label": "", "metadata": {}, "score": "58.0645"}
{"text": "Patient education is a key part of achieving concordance .Conclusions .The results of this study suggest that women , newly diagnosed patients , those with a high score on the DUSI - R psychiatric disorder scale , and subjects with high educational degrees , at least in the context of this study , seem to have a higher risk of non - adherence .", "label": "", "metadata": {}, "score": "58.11287"}
{"text": "The findings of improvement in measures of cognitive functioning ( CDR ) and in the inattentive subtype of ADHD add to a growing literature on the usefulness of mixed catecholaminergic reuptake inhibitors [ 33 ] on ADHD .", "label": "", "metadata": {}, "score": "58.113567"}
{"text": "Results .Subjects and disposition .Baseline characteristics are shown in Table 2 .The completer population included 67 subjects ( 69.1 % ) in the placebo arm , 55 subjects ( 63.2 % ) in the 54-mg arm and 54 subjects ( 58.6 % ) in the 72-mg arm .", "label": "", "metadata": {}, "score": "58.127834"}
{"text": "An alpha level of 0.10 was used to judge the statistical significance of an interaction .No correction was done for multiple testing as this is a post hoc analysis on existing data .", "label": "", "metadata": {}, "score": "58.14247"}
{"text": "This model is appropriate for the analysis of a binary variable ( adherent / non - adherent ) , while it also incorporates the longitudinal design ( one outcome per day per patient ) as a hierarchical structure in which daily adherence is nested within patient [ 22 ] .", "label": "", "metadata": {}, "score": "58.19947"}
{"text": "In both age groups , correlations between the ADHD core symptoms and the HR - QoL were small to moderate at endpoint and with regard to the change from baseline .", "label": "", "metadata": {}, "score": "58.24683"}
{"text": "In studies 2 and 3 , baseline Clinical Global Impression of Severity ( CGI - S ) [ 44 ] scores for ADHD were at least 4 or higher .", "label": "", "metadata": {}, "score": "58.33707"}
{"text": "Eur Child Adolesc Psychiatry .10.1007/s00787 - 006 - 0549 - 0 .View Article PubMed .Arnold LE , Christopher J , Huestis R , Smeltzer DJ : Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction : controlled comparison by placebo washout design with Bayes ' analysis .", "label": "", "metadata": {}, "score": "58.468014"}
{"text": "Additionally , we analyzed the correlation between ADHD core symptoms and HR - QoL at baseline , at endpoint , and for change from baseline in order to evaluate the association between the improvement of the core symptoms and the improvement of HR - QoL. Treatment effects were assessed based on the 3 placebo - controlled trials and correlations were examined leveraging all 5 studies found in the Lilly data base .", "label": "", "metadata": {}, "score": "58.531185"}
{"text": "3.5 Differences in correlations between ADHD - RS and CHIP - CE scores , across age groups .No substantial age differences with respect to the correlations between ADHD - RS and CHIP - CE scores were found .", "label": "", "metadata": {}, "score": "58.561104"}
{"text": "There were a number of strengths of this study , including a clinically relevant dosing regimen , a considerable number of female and minority participants , and the inclusion of both children and adolescents .", "label": "", "metadata": {}, "score": "58.591522"}
{"text": "Biederman et al previously described full inclusion / exclusion criteria [ 17 ] .Study Design .The study comprised a 1-week screening period ; a 1-week washout period of prior psychoactive medications ; and 4-weeks of double - blind treatment .", "label": "", "metadata": {}, "score": "58.689766"}
{"text": "In addition , several studies have shown improvement of emotional well - being and HR - QoL in children and adolescents treated with atomoxetine [ 15 , 18 - 25 ] .", "label": "", "metadata": {}, "score": "58.70641"}
{"text": "All subtypes of ADHD were allowed to enroll in the study .Patients currently ( within the past 6 months ) known to abuse or to be dependent on any drug , including alcohol or a positive urine drug screen for cocaine , heroin , or marijuana were excluded .", "label": "", "metadata": {}, "score": "58.74604"}
{"text": "Change from baseline scores for Power of Attention over the study period ( Mean + /- SEM ) .Improvements from baseline are plotted to ascend .", "label": "", "metadata": {}, "score": "58.862885"}
{"text": "Factors associated with reduced adherence in the present study included score on the DUSI - R psychiatric disorder scale , completing university versus high school , and shorter time since diagnosis of ADHD ; and men were more adherent than women .", "label": "", "metadata": {}, "score": "58.895405"}
{"text": "In this phase 3 , double - blind , placebo - controlled trial , children and adolescents with hyperactive- or combined - subtype ADHD who had an inadequate response to their stable stimulant regimen were randomized to receive CLON - XR or placebo in combination with their baseline stimulant medication .", "label": "", "metadata": {}, "score": "59.23622"}
{"text": "In the completer analysis , there was no significant difference in adherence between OROS MPH groups and placebo ( Table 4 ) .In addition , male sex , DUSI psychiatric disorder score and time since ADHD diagnosis were no longer significantly related to adherence ( and therefore do not appear in the final model , as shown in Table 4 ) , but DUSI health status score at baseline was .", "label": "", "metadata": {}, "score": "59.327766"}
{"text": "ADHD - RS .The evaluation of the treatment effect of atomoxetine on core ADHD symptoms was based on the ADHD - RS [41 ] , which evaluates all 18 symptoms of ADHD according to the DSM - IV diagnostic criteria .", "label": "", "metadata": {}, "score": "59.345226"}
{"text": "Steele et al [ 23 ] suggested that treatment response be considered as an improvement in symptom scores from baseline of 25 % to 30 % .", "label": "", "metadata": {}, "score": "59.351997"}
{"text": "Total scores range from 0 to 32 , with increasing score reflecting greater sleepiness .Change From Baseline in Health Utilities Index-2/3 ( HUI 2/3 ) Scores at Week 8 - LOCF [ Time Frame : Baseline and up to 8 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "59.3928"}
{"text": "Changes in ADHD - RS - IV and CGI - I Scores : Remitters and Responders .Of the 26 nonremitters on prior MPH at screening , 12 ( 63.2 % ) participants receiving LDX and 1 ( 14.3 % ) receiving placebo were classified as remitters during the study ( Figure 3 ) .", "label": "", "metadata": {}, "score": "59.55314"}
{"text": "Table 2 . Discussion .The results of this 8 week controlled study indicate that for both primary and secondary clinical outcomes , there were no clinically or statistically significant effects of NS2359 in ADHD symptoms compared to placebo for the overall study population .", "label": "", "metadata": {}, "score": "59.616238"}
{"text": "Baseline impairments in HR - QoL as measured by the CHIP - CE were seen on several dimensions ( e.g. , Satisfaction with Self , Threats to Achievement , and Academic Performance ) in both age groups .", "label": "", "metadata": {}, "score": "59.62564"}
{"text": "View Article PubMed .Spencer T : ADHD treatment across the life cycle .J Clin Psychiatry .View Article PubMed .Safren SA , Otto MW , Wilens T , Sprich S , Biederman J , Winette C : Cognitive - behavioral therapy for residual ADHD in adults .", "label": "", "metadata": {}, "score": "59.765648"}
{"text": "The primary efficacy outcome was the change from baseline score at endpoint on the ADHD - RS - IV total scores .Endpoint was defined as the last post - randomization treatment week for which a valid score was obtained prior to dose tapering ( up to Week 8) .", "label": "", "metadata": {}, "score": "59.87542"}
{"text": "The present findings provide evidence for added efficacy of CLON - XR when treating ADHD youth with inadequate response to stimulants .These results indicate that the extended - release formulation of a nonstimulant medication is a useful addition to currently available treatments for patients with ADHD .", "label": "", "metadata": {}, "score": "59.936104"}
{"text": "Change From Baseline in Pediatric Daytime Sleepiness Scale ( PDSS )Total Score at Week 8 - LOCF [ Time Frame : Baseline and up to 8 weeks ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "59.944344"}
{"text": "Mean scores range from 0 to 3 .Known history or presence of structural cardiac abnormalities , serious heart rhythm abnormalities , syncope , cardiac conduction problems , exercise - related cardiac events , or clinically significant bradycardia ; orthostatic hypotension or controlled or uncontrolled hypertension .", "label": "", "metadata": {}, "score": "59.966133"}
{"text": "Participants with severe symptoms at baseline may be considered responders but still exhibit symptoms .Hence , a clinical response definition that includes a percent reduction in symptoms and a measure of global clinical improvement , such as the CGI - I , may be a better measure of clinical response to treatment .", "label": "", "metadata": {}, "score": "59.990776"}
{"text": "Data of 794 subjects ( 611 children , 183 adolescents ) were pooled .Treatment effect of atomoxetine was significant in both age groups for the Risk Avoidance domain and its subdomains .", "label": "", "metadata": {}, "score": "60.016296"}
{"text": "The relatively strong correlation between the Risk Avoidance domain and ADHD - RS total score was predominantly influenced by the correlation with the hyperactive / impulsive ADHD - RS sub - score , while the inattentive sub - score exerted greater influence on the correlations between the Achievement domain and the ADHD - RS scores .", "label": "", "metadata": {}, "score": "60.19855"}
{"text": "DSM IV ADHD Rating Scale ( ADHD - RS ) adolescent informant , ascertained at baseline and weekly throughout the 16 week study .This scale is an 18-item symptom checklist of self - reported adolescent ADHD symptoms .", "label": "", "metadata": {}, "score": "60.208344"}
{"text": "Higher scores are indicative of increased ADHD .This scale allows parents to respond on the basis of the child 's behavior and help assess ADHD and evaluate problem behavior .", "label": "", "metadata": {}, "score": "60.29477"}
{"text": "Change in ADHD symtoms and functional outcomes in Canadian Children during 3 Months of atomoxetine treatment .American Psychiatric Association .Diagnostic and Statistical Manual of Mental Disorders , Text Revision ( DSM - IV - TR ) Fourth .", "label": "", "metadata": {}, "score": "60.315998"}
{"text": "OBJECTIVE :To assess the efficacy and safety of clonidine hydrochloride extended - release tablets ( CLON - XR ) combined with stimulants ( ie , methylphenidate or amphetamine ) for attention - deficit / hyperactivity disorder ( ADHD ) .", "label": "", "metadata": {}, "score": "60.513523"}
{"text": "ADHD was consistently associated with complex short - term and long - term impairments and negative outcomes regarding educational achievement , social and emotional impairment , behavioral disturbances , problems with interpersonal relations , and psychiatric comorbidity [ 2 - 5 ] .", "label": "", "metadata": {}, "score": "60.55882"}
{"text": "However , it should be noted that these correlations do not fully explain the background of the impaired HR - QoL in children and adolescents with ADHD .", "label": "", "metadata": {}, "score": "60.593296"}
{"text": "Ethikkommission der Medizinischen Fakult\u00e4t der Heinrich - Heine - Universit\u00e4t .Switzerland .Assessments .The primary efficacy variable in the study was the investigator - rated CAARS : O - SV , which was assessed after 1 week and then every 2 weeks thereafter .", "label": "", "metadata": {}, "score": "60.64298"}
{"text": "For the evaluation of the effect of atomoxetine on HR - QoL , as measured by the CHIP - CE , samples from only the placebo - controlled trials were included .", "label": "", "metadata": {}, "score": "60.67926"}
{"text": "The pooled analysis evaluated results from these patients on a weight adjusted mg / kg basis from two similarly designed , randomized , double - blind , forced - dose titration , multicenter phase III trials .", "label": "", "metadata": {}, "score": "60.853302"}
{"text": "Our combined findings of an overall lack of response coupled with evidence of improvement in the inattentive subtype and CDR suggest an overall pro - cognitive effect of the medication in ADHD .", "label": "", "metadata": {}, "score": "60.924675"}
{"text": "Mean adherence in patients who completed the study and in those who discontinued .No systematic trend in adherence could be found .Predictors of adherence .", "label": "", "metadata": {}, "score": "60.93429"}
{"text": "Participants will be scheduled for weekly medication and research assessment visits ( approximately 45 minutes to 1 hour in length ) .Participants will also attend weekly CBT sessions ( approximately 1 hour in length ) targeting their drug use .", "label": "", "metadata": {}, "score": "61.121254"}
{"text": "In both studies , the types of adverse events appear to be generally consistent with the known safety profile for Vyvanse established in studies of adolescents with ADHD . \" Treatment decisions for adolescents are complex as they are in a state of transition into adulthood and they experience greater challenges in school , home , and social settings .", "label": "", "metadata": {}, "score": "61.22361"}
{"text": "Background .Medication non - adherence has an important impact on treatment efficacy and healthcare burden across a range of conditions and therapeutic areas .The aim of this analysis was to determine predictors of non - adherence and impact of non - adherence on treatment response in adults with attention - deficit / hyperactivity disorder ( ADHD ) .", "label": "", "metadata": {}, "score": "61.411076"}
{"text": "In the current study , there were no serious side effects or reports of withdrawal symptomatology and no clinically meaningful cardiovascular or other laboratory abnormalities were detected .", "label": "", "metadata": {}, "score": "61.520287"}
{"text": "Only the final model is presented in this manuscript .Restricted likelihood distance and Cook 's d were used to detect influential observations .No influential observations were dropped .", "label": "", "metadata": {}, "score": "61.52127"}
{"text": "The results of this meta - analysis need to be interpreted in light of a number of limitations .First , the samples of the five clinical trials showed heterogeneity in terms of cultural diversity , history of stimulant medication , and comorbidity .", "label": "", "metadata": {}, "score": "61.66143"}
{"text": "First , this study excluded patients with significant psychiatric comorbidity .Given the high rates of comorbidity in individuals diagnosed with ADHD , 3 , - , 5 the sample may therefore not be representative of many patients who are treated for ADHD .", "label": "", "metadata": {}, "score": "61.716076"}
{"text": "[ Time Frame : Baseline and up to 8 weeks ] [ Designated as safety issue : No ] .The ADHD - RS - IV consists of 18 items scored on a 4-point scale ranging from 0 ( no symptoms ) to 3 ( severe symptoms ) with total score ranging from 0 to 54 .", "label": "", "metadata": {}, "score": "61.7586"}
{"text": "The systolic BP change for all LDX groups ranged from 0.4 ( 1.08 ) to 2.6 ( 1.05 ) mm Hg and for placebo was 1.3 ( 1.05 ) mm Hg .", "label": "", "metadata": {}, "score": "61.820488"}
{"text": "Demographic data of the pooled sample are summarized in Table \u200b Table3 3 . 3.2 Baseline differences across age groups .In the population of the five studies , gender distribution was similar across age groups .", "label": "", "metadata": {}, "score": "61.85011"}
{"text": "Most importantly , the sample size was large .Secondly , three of the five studies were placebo - controlled .Thirdly , the analysis was based on individual patient data rather than publication - based meta - analysis .", "label": "", "metadata": {}, "score": "62.062874"}
{"text": "Post Hoc Efficacy Analyses .This post hoc efficacy analysis assessed treatment effects of LDX and placebo in participants receiving MPH prior to entering the present study , who had available screening data and significant ADHD symptoms prior to discontinuing their MPH regimen .", "label": "", "metadata": {}, "score": "62.075783"}
{"text": "A randomized , controlled trial may not be the best setting in which to evaluate adherence , which may be higher than in the ' real world , ' as suggested by previous small studies in adults with ADHD [ 7 , 8 ] .", "label": "", "metadata": {}, "score": "62.10643"}
{"text": "SD : standard deviation ; SE : standard error ; LS Mean : least - squares mean ; CI : unadjusted confidence interval .a Treatment was given in combination with a psychostimulant .", "label": "", "metadata": {}, "score": "62.294098"}
{"text": "In addition , patients were grouped as Inattentive or Combined according to DSM - IV [ 26 ] and it was investigated whether treatment interacted with these categories .", "label": "", "metadata": {}, "score": "62.578945"}
{"text": "After baseline assessment , all patients underwent a 1- to 2-week washout period , during which any ADHD medications except methylphenidate- or amphetamine - based products were discontinued .", "label": "", "metadata": {}, "score": "62.583496"}
{"text": "In addition , stimulant medication was not explicitly optimized for each patient during the course of the study .It is unknown what effects CLON - XR would have had if a formal optimization phase had been used .", "label": "", "metadata": {}, "score": "62.66325"}
{"text": "This post hoc analysis has limitations .The classification of participants as nonremitters on prior MPH considers only the ADHD - RS - IV total score at screening and may not reflect the participants ' overall clinical response to MPH .", "label": "", "metadata": {}, "score": "62.733315"}
{"text": "View Article PubMed .Bosworth J , Jensen NO , Oliver S , Wesnes KA : First cognitive effects of NS2359 , a noradrenalin , dopamine & serotonin reuptake inhibitor , in volunteers .", "label": "", "metadata": {}, "score": "62.77797"}
{"text": "However , a greater percentage of patients in the CLON - XR plus stimulant group ( 15 % ) decreased their dose of stimulant compared with the placebo plus stimulant group ( 9 % ; Fig 4 ) .", "label": "", "metadata": {}, "score": "62.78483"}
{"text": "This needs to be taken into account when evaluating the clinical impact of the differences .The developers of the CHIP - CE have proposed that a threshold of 0.6 standard deviations is clinically meaningful [ 49 ] .", "label": "", "metadata": {}, "score": "62.805008"}
{"text": "pp .218 - 222 .Coghill D , Danckaerts M , Sonuga - Barke E , Sergeant J. ADHD European Guidelines Group .Practitioner review : quality of life in child mental health - conceptual challenges and practical choices .", "label": "", "metadata": {}, "score": "62.9267"}
{"text": "The correlation values with the 95 % CI are summarized in Table \u200b Table7 , 7 , \u200b , 8 , 8 , \u200b , 9 9 and Figure \u200b Figure2 2 and \u200b and3 , 3 , by age groups .", "label": "", "metadata": {}, "score": "62.942688"}
{"text": "Similarly , no apparent differences occurred between the NNTs to achieve clinical response or symptomatic remission for the overall efficacy population and nonremitters on prior MPH .", "label": "", "metadata": {}, "score": "62.946854"}
{"text": "Endpoint was defined as the last post - randomization treatment week for which a valid score was obtained prior to dose tapering ( up to Week 5 in Study 1 and up to Week 6 in Study 2 ) .", "label": "", "metadata": {}, "score": "63.0703"}
{"text": "Factors significantly associated with non - adherence included female sex , shorter time since ADHD diagnosis , higher education level ( completion of university ) and score on the Drug Use Screening Inventory psychiatric disorders subscale .", "label": "", "metadata": {}, "score": "63.13212"}
{"text": "10.1016/j.neuropharm.2009.08.020 .View Article PubMed .Faraone SV , Buitelaar J : Comparing the efficacy of stimulants for ADHD in children and adolescents using meta - analysis .", "label": "", "metadata": {}, "score": "63.14585"}
{"text": "In a previous trial , the efficacy of CLON - XR as monotherapy for treating ADHD in children and adolescents was demonstrated .18 In this trial it also is suggested that CLON - XR used in combination with stimulants for the treatment of ADHD youth is well tolerated .", "label": "", "metadata": {}, "score": "63.147865"}
{"text": "Safety .Somnolence , headache , fatigue , upper abdominal pain , and nasal congestion were the most commonly reported TEAEs in the CLON - XR plus stimulant group ( Table 4 ) .", "label": "", "metadata": {}, "score": "63.164352"}
{"text": "Mean systolic and diastolic blood pressure decreased slightly in patients in the CLON - XR plus stimulant group during the study , whereas no change or a 1 mm Hg increase was observed in patients receiving placebo plus stimulant ( Table 5 ) .", "label": "", "metadata": {}, "score": "63.17708"}
{"text": "In a randomized controlled trial ( RCT ) , LDX was associated with improvements in clinical symptoms of ADHD in children while maintaining a safety profile similar to other stimulant medications [ 17 ] .", "label": "", "metadata": {}, "score": "63.26225"}
{"text": "Results . 3.1 Subjects .A total of 180 subjects were screened at the 3 study sites .Of the 54 patients not randomized 32 did not meet the study inclusion / exclusion criteria , 14 withdrew their consent to participate in the study and 8 were excluded for other reasons .", "label": "", "metadata": {}, "score": "63.31108"}
{"text": "Scoring ranges from 0.00 ( dead ) to 1.00 ( perfect health ) .Higher scores represent better health status .Change From Baseline in Conner 's Parent Rating Scale - Revised Short Version ( CPRS - R : S ) Score at Week 8 - LOCF [ Time Frame : Baseline and up to 8 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "63.391285"}
{"text": "ADORE Study Group .Factors related to health - related quality of life ( HRQoL ) among children with ADHD in Europe at entry into treatment .", "label": "", "metadata": {}, "score": "63.40856"}
{"text": "doi : 10.1186/1753 - 2000 - 2 - 11 .[ PMC free article ] [ PubMed ] [ Cross Ref ] .Barkley RA , Fischer M , Smallish L , Fletcher K. The persistence of attention - deficit / hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder .", "label": "", "metadata": {}, "score": "63.44027"}
{"text": "PubMed View Article .Velligan DI , Wang M , Diamond P , Glahn DC , Castillo D , Bendle S , Lam YW , Ereshefsky L , Miller AL : Relationships among subjective and objective measures of adherence to oral antipsychotic medications .", "label": "", "metadata": {}, "score": "63.520897"}
{"text": "2.1 Studies included in the meta - analysis .Data from 5 atomoxetine clinical trials ( 4 from Europe , 1 from Canada ) with similar inclusion and exclusion criteria and similar duration of treatment ( 8 - 12 weeks follow - up ) were included in the meta - analysis [ 23 , 36 - 39 ] .", "label": "", "metadata": {}, "score": "63.583992"}
{"text": "The Cognitive Drug Research ( CDR ) computerized assessment system was used to assess cognitive function in this study .The system has been widely used in clinical research [ 26 , 27 ] and was used previously to identify the positive effects of with NS 2359 on attention and memory in healthy volunteers [ 22 ] .", "label": "", "metadata": {}, "score": "63.64222"}
{"text": "Baseline ADHD - RS - IV total scores were 36.6 , 37.8 , and 38.2 for Vyvanse , Concerta , and placebo , respectively .At the end of the study [ Week 8 ( Visit 8) ] , patients treated with Vyvanse experienced a mean 25.6 point reduction in ADHD - RS - IV total score compared with a 23.5 point reduction for Concerta , and a 13.4 point reduction for placebo .", "label": "", "metadata": {}, "score": "63.660076"}
{"text": "doi : 10.1111/j.1469 - 7610.2009.02008.x .[PubMed ] [ Cross Ref ] .Goodman D , Faraone SV , Adler LA , Dirks B , Hamdani M , Weisler R. Interpreting ADHD Rating Scale Scores :", "label": "", "metadata": {}, "score": "63.69103"}
{"text": "Analyses by age revealed a statistically significant treatment effect only in the 6 - 12 age subgroup .Due to the relatively small proportion of adolescent patients ( ages 13 - 17 ) enrolled into these studies ( approximately 25 % ) , these data may not have been sufficient to demonstrate efficacy in the adolescent patients .", "label": "", "metadata": {}, "score": "63.993607"}
{"text": "Conclusion .In this analysis , children with significant clinical ADHD symptoms despite MPH treatment improved during treatment with LDX and experienced similar improvements in their symptoms as the overall study population .", "label": "", "metadata": {}, "score": "64.015274"}
{"text": "Drug Interaction Studies .Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be affected significantly by CYP3A4 inhibitors or inducers ( Figure 2 ) .", "label": "", "metadata": {}, "score": "64.018555"}
{"text": "Therefore , some adolescent patients were randomized to a dose that might have resulted in relatively lower plasma guanfacine concentrations compared to the younger patients .", "label": "", "metadata": {}, "score": "64.15401"}
{"text": "The Restricted Activity sub - domain showed a significant difference between children and adolescents ; however , mean and SD in this sub - domain were within the normal range , indicating relevant impairment neither in children nor in adolescents . 3.3 Treatment effect of atomoxetine .", "label": "", "metadata": {}, "score": "64.18332"}
{"text": "View Article .Faraone SV , Sergeant J , Gillberg C , Biederman J : The Worldwide Prevalence of ADHD : Is it an American Condition ?", "label": "", "metadata": {}, "score": "64.2471"}
{"text": "Atomoxetine was generally shown to be effective in improving certain aspects of HR - QoL as reflected by the CHIP - CE .In the Risk Avoidance domain and Threats to Achievement sub - domain , there was a significant age effect with better efficacy seen in adolescents .", "label": "", "metadata": {}, "score": "64.2549"}
{"text": "The methods used in this study for the overall study population have been described previously [ 17 ] .This was a multicenter , randomized , double - blind , forced - dose titration , parallel - group study , conducted in accordance with the Guideline for Good Clinical Practice from the World Health Organization and the Declaration of Helsinki and its amendments .", "label": "", "metadata": {}, "score": "64.26108"}
{"text": "Mean ( SD ) morning , afternoon , and evening CPRS - R ADHD index scores at baseline and endpoint in nonremitters on prior MPH are shown in Figure 5 .", "label": "", "metadata": {}, "score": "64.27746"}
{"text": "No serious adverse events were reported during or following the study .There were no clinically significant changes in the measured blood and urine parameters that were evaluated to be related to the treatment .", "label": "", "metadata": {}, "score": "64.332245"}
{"text": "Dose - responsive efficacy was evident , particularly when data were examined on a weight - adjusted ( mg / kg ) basis .When evaluated over the dose range of 0.01 - 0.17 mg / kg / day , clinically relevant improvements were observed beginning at doses in the range 0.05 - 0.08 mg / kg / day .", "label": "", "metadata": {}, "score": "64.54292"}
{"text": "Clin Ther .10.1016/j.clinthera.2006.11.006 .View Article PubMed .Goodman D , Faraone SV , Adler LA , Dirks B , Hamdani M , Weisler R : Interpreting ADHD rating scale scores : linking ADHD rating scale scores and CGI levels in two randomized controlled trials of lisdexamfetamine dimesylate in ADHD .", "label": "", "metadata": {}, "score": "64.72367"}
{"text": "Although there is no cure for ADHD , there are accepted treatments that have been demonstrated to improve symptoms .Standard treatments include educational approaches , psychological therapies which may include behavioral modification , and/or medication .", "label": "", "metadata": {}, "score": "64.733826"}
{"text": "Table \u200b Table2 2 explains which aspects of HR - QoL are assessed by each domain of the CHIP - CE .More recently , a CHIP - CE total score has been developed , which can be used as a global measure of HR - QoL [ 35 ] .", "label": "", "metadata": {}, "score": "64.83676"}
{"text": "JD is a consultant working on behalf of SGS - Life Science Services , a company employed by Janssen - Cilag EMEA to provide statistical analysis .", "label": "", "metadata": {}, "score": "64.94212"}
{"text": "Conclusions .In this post hoc analysis of children who had significant clinical ADHD symptoms despite previous MPH treatment , LDX demonstrated efficacy and clinical response in the subpopulation assessed .", "label": "", "metadata": {}, "score": "64.984406"}
{"text": "Faries DE , Yalcin I , Harder D , Heiligenstein JH : Validation of the ADHD Rating Scale as a clinician administered and scored instrument .", "label": "", "metadata": {}, "score": "65.11516"}
{"text": "In the population of the five studies , gender distribution was similar across age groups .As the studies were not designed to include the same proportion of boys across different age - groups , this finding is surprising .", "label": "", "metadata": {}, "score": "65.19872"}
{"text": "Endpoint was defined as the last post - randomization treatment week prior to dose tapering for which a valid score was obtained ( up to Week 8) .", "label": "", "metadata": {}, "score": "65.22213"}
{"text": "This study was supported by Addrenex Pharmaceuticals Inc , a Shionogi company .Medical writing assistance was provided under the direction of Dr Kollins by MedThink SciCom Inc with support from Shionogi Inc. .", "label": "", "metadata": {}, "score": "65.29547"}
{"text": "As well , patterns of symptomatic remission were similar with placebo treatment in the overall efficacy population and in nonremitters on prior MPH .The NNT ( 95 % CI ) to achieve symptomatic remission with LDX at treatment endpoint was 2.0 ( 1.21 , 6.63 ) in nonremitters and 2.1 ( 1.74 , 2.72 ) in the overall study population .", "label": "", "metadata": {}, "score": "65.33438"}
{"text": "A trend for improvement was also seen to working memory .These improvements are in major domains of cognitive function and have the potential for clinical relevance in ADHD patients .", "label": "", "metadata": {}, "score": "65.369835"}
{"text": "Adherence .Mean ( \u00b1 SD ) adherence was 92.6 % \u00b1 17.6 and 93.3 % \u00b1 13.4 in the 54- and 72-mg / day OROS MPH groups , respectively , versus 97.5 % \u00b1 6.8 in the placebo group ( main analysis set ) .", "label": "", "metadata": {}, "score": "65.40045"}
{"text": "Patient self - report ADHD - RS .The Conners ( CAARS ) .The Brown Adult Scale ( BROWN - AS ) .The Clinical Global Impression ( CGI ) .", "label": "", "metadata": {}, "score": "65.43478"}
{"text": "Before week 5 , physicians were allowed to adjust the dose of CLON - XR by not escalating the dose to the maximal amount for the study ( ie , 0.4 mg per day ) or by tapering the dose by 0.1 mg per week if safety concerns arose .", "label": "", "metadata": {}, "score": "65.47337"}
{"text": "Similarly , in our meta - analysis clinically relevant impairments were found in the Risk Avoidance and Achievement domains ( and in their sub - domains ) , in the Emotional Comfort and in the Satisfaction with Self sub - domains as well as Family involvement and Social Problem Solving .", "label": "", "metadata": {}, "score": "65.488625"}
{"text": "THIS SUBJECT : .Two small studies have evaluated the safety and efficacy of immediate - release clonidine plus stimulant medication to treat attention - deficit / hyperactivity disorder ( ADHD ) .", "label": "", "metadata": {}, "score": "65.59505"}
{"text": "Efficacy .When stimulant class was incorporated into the primary efficacy analysis , no statistically significant difference versus placebo was observed between the CLON - XR plus methylphenidate and CLON - XR plus amphetamine groups ( Fig 3 ) .", "label": "", "metadata": {}, "score": "65.68857"}
{"text": "The mean ( SD ) change in ADHD - RS - IV total score from baseline with LDX treatment was -24.0 ( 12.56 ) ( Figure 2 ) , corresponding to a mean ( SD ) percentage reduction of 57 ( 29.9 % ) in the 19 nonremitters on prior MPH treatment .", "label": "", "metadata": {}, "score": "65.699104"}
{"text": "Research shows a high prevalence of Attention Deficit Hyperactivity Disorder ( ADHD ) in adolescents with substance abuse disorders and indicates that they have poorer substance use treatment outcomes and poorer prognosis and risk of persistence and progression of drug use and behavior problems into adulthood .", "label": "", "metadata": {}, "score": "65.750565"}
{"text": "Abuse liability assessment of atomoxetine in a drug - abusing population .Drug and Alcohol Dependence .doi : 10.1016/j.drugalcdep.2008.01.008 .[PubMed ] [ Cross Ref ] .", "label": "", "metadata": {}, "score": "65.80322"}
{"text": "Investigators were also allowed to adjust the dose of stimulant medication on the basis of the efficacy and safety profile of the patient ; however , the category of stimulant could not be altered .", "label": "", "metadata": {}, "score": "65.83201"}
{"text": "All randomized subjects began the treatment protocol .A total of 31 subjects either did not complete the 8-week treatment period or had a missing primary endpoint at week 0 and/or week 8 .", "label": "", "metadata": {}, "score": "65.840385"}
{"text": "While the precise etiology of ADHD is unknown continued interest has been focused on the role of the catecholaminergic and nicotinic / cholinergic systems in ADHD .", "label": "", "metadata": {}, "score": "65.86771"}
{"text": "Recent epidemiological data suggest that ADHD occurs in 4.4 % of adults in the US [ 4 ] .ADHD in adults is associated with academic , employment , and marital difficulties , as well as comorbid psychiatric disorders such as substance abuse , depression , anxiety , and personality disorders [ 5 - 7 ] .", "label": "", "metadata": {}, "score": "65.8911"}
{"text": "The CHIP - CE scores are standardized to t scores with a mean ( \u00b1 SD ) of 50 ( \u00b1 10 ) , with higher scores indicating better health .", "label": "", "metadata": {}, "score": "65.91579"}
{"text": "Finally the improvement to Quality of Episodic Secondary Memory with the active medication indicated that subjects were better able to encode , store and retrieve verbal and pictorial information of an episodic nature .", "label": "", "metadata": {}, "score": "65.971725"}
{"text": "The Hamilton Depression Scale ( HAM - D ) was completed by the physician at screening ( patients being excluded if the score exceeded 15 ) , baseline ( week 0 ) and at the end of treatment ( week 8) .", "label": "", "metadata": {}, "score": "66.142914"}
{"text": "These studies have shown robust negative effects on HR - QoL as reported both by parents and in patient self - reports .However , children with ADHD tend to rate their own HR - QoL less negatively than their parents and do not always see themselves as functioning less well than healthy controls [ 6 ] .", "label": "", "metadata": {}, "score": "66.327194"}
{"text": "The factor structure of the full CDR task battery has been investigated using Principal Components Analysis [ 30 ] .This analysis confirmed the construct validity of the battery by demonstrating that the task variables within theorized cognitive domains of attention , working memory and episodic secondary memory , loaded together on five common factors .", "label": "", "metadata": {}, "score": "66.382355"}
{"text": "Authors ' contributions .JJSK was an investigator in the LAMDA - II trial , and was involved in the interpretation of the data , and the drafting and reviewing of the manuscript .", "label": "", "metadata": {}, "score": "66.409515"}
{"text": "The drug was provided as tablets of 0.25 mg or corresponding placebo tablets . 2.2Assessments .The primary efficacy endpoint was the ADHD - rating scale ( investigator - rated ) which was administered at all study visits .", "label": "", "metadata": {}, "score": "66.48358"}
{"text": "This might have influenced the results in the sense that the parents and patients might have provided different responses , especially when evaluating adolescents .The views of the young people themselves , however , need to be sought in addition to parent reports , as the patient perspective reflects the subjective well - being of these children and adolescents and takes into account their autonomy as individuals [ 45 ] .", "label": "", "metadata": {}, "score": "66.56974"}
{"text": "Specifically , hyperactive / impulsive symptoms generally decline , while inattentive symptoms might persist , or even become relatively more pronounced , taking into consideration the increased complexity of those cognitive tasks that a child or an adolescent is exposed to [ 3 , 30 ] .", "label": "", "metadata": {}, "score": "66.65445"}
{"text": "Formerly of Shire Canada Inc. .References .Pliszka S , the AACAP Work Group on Quality Issues : Practice parameter for the assessment and treatment of children and adolescents with attention - deficit / hyperactivity disorder .", "label": "", "metadata": {}, "score": "66.82314"}
{"text": "Exclusion criteria included a known history of cardiovascular disease , clinically significant ECG , blood pressure exceeding the 90th percentile for age , sex and height , current psychiatric diagnosis and a history of substance abuse or dependence .", "label": "", "metadata": {}, "score": "66.844315"}
{"text": "Results .Mean adherence was 92.6 % and 93.3 % ( OROS MPH 54 and 72 mg / day , respectively ) , versus 97.5 % ( placebo ) .", "label": "", "metadata": {}, "score": "66.95493"}
{"text": "LAMDA - II was a 13-week randomized , double - blind , multicentre study in adults with ADHD randomly allocated to OROS MPH 54 or 72 mg / day , or placebo [ 18 ] .", "label": "", "metadata": {}, "score": "66.96989"}
{"text": "Eur Child Adolesc Psychiatry .doi : 10.1007/s00787 - 007 - 0603 - 6 .[PubMed ] [ Cross Ref ] .Bastiaens L. Both atomoxetine and stimulants improve quality of life in an ADHD population treated in a community clinic .", "label": "", "metadata": {}, "score": "66.999565"}
{"text": "Biol Psychiatry 2008 , 63 : 981 - 989 .PubMed View Article .World J Biol Psychiatry 2011 .Epub ahead of print .Conners C , Erhardt D , Sparrow E : Conners ' Adult ADHD Rating Scales ( CAARS ) : Technical Manual .", "label": "", "metadata": {}, "score": "67.10643"}
{"text": "Darredeau C , Barrett SP , Jardin B , Pihl RO : Patterns and predictors of medication compliance , diversion , and misuse in adult prescribed methylphenidate users .", "label": "", "metadata": {}, "score": "67.13435"}
{"text": "Currently , the treatment of ADHD in adults is largely predicated upon use of both stimulant and non - stimulant medications , as well as adjunctive structured psychotherapies [ 10 ] .", "label": "", "metadata": {}, "score": "67.303635"}
{"text": "Effect size ( Cohen 's d ) was calculated for treatment overall and within age subgroups .Effect size was calculated as the ratio of the difference between atomoxetine and placebo at endpoint divided by the standard deviation of the residuals .", "label": "", "metadata": {}, "score": "67.34793"}
{"text": "Trial registration . EudraCT # : 2007 - 002111 - 82 .Keywords .Adherence Adults ADHD CAARS : O - SV Efficacy Compliance Non - adherence OROS methylphenidate .", "label": "", "metadata": {}, "score": "67.36732"}
{"text": "Treatment with CLON - XR plus stimulant was well tolerated , with 1 patient in the CLON - XR plus stimulant group discontinuing because of TEAEs versus 3 patients in the placebo plus stimulant group .", "label": "", "metadata": {}, "score": "67.49465"}
{"text": "Patient Disposition .One patient in the placebo plus stimulant group was omitted from the ITT population because of a lack of study assessment after baseline .", "label": "", "metadata": {}, "score": "67.57887"}
{"text": "Exposure to guanfacine was higher in children ( ages 6 - 12 ) compared to adolescents ( ages 13 - 17 ) and adults .After oral administration of multiple doses of INTUNIV \u00ae 4 mg , the Cmax was 10 ng / mL compared to 7 ng / mL and the AUC was 162 ng h / mL compared to 116 ng h / mL in children ( ages 6 - 12 ) and adolescents ( ages 1317 ) , respectively .", "label": "", "metadata": {}, "score": "67.65106"}
{"text": "A dose of 0.5 mg / day NS2359 was shown to give DA occupancy of 35 % , which is in the range of other clinically efficacious compounds used for treatment of ADHD patients [ 35 ] .", "label": "", "metadata": {}, "score": "67.712204"}
{"text": "WHAT THIS STUDY ADDS : .In this study information on the safety and efficacy of extended - release clonidine combined with stimulant medication for the treatment of ADHD is provided .", "label": "", "metadata": {}, "score": "67.828545"}
{"text": "The ADHD - RS - IV , CGI - S , and CGI - I were completed by the investigator , whereas the CPRS and PGA were evaluated by parents / guardians .", "label": "", "metadata": {}, "score": "67.8292"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT00997984 .Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Dyskinesias Mental Disorders Mental Disorders Diagnosed in Childhood Nervous System Diseases Neurologic Manifestations Signs and Symptoms Guanfacine Adrenergic Agents .", "label": "", "metadata": {}, "score": "67.83922"}
{"text": "Conclusion .The results of this analysis suggest that newly diagnosed patients , those with a high score on the DUSI - R psychiatric disorder scale , women , and subjects with high educational degrees may be at increased risk of non - adherence .", "label": "", "metadata": {}, "score": "68.11023"}
{"text": "Sixteen ( 16 ) patients on Vyvanse , 15 patients on Concerta , and 1 patient on placebo had TEAEs that led to study discontinuation .", "label": "", "metadata": {}, "score": "68.1201"}
{"text": "Dr. Keith Wesnes is sole shareholder of CDR Ltd , which received financial support to supply the cognitive tests in the study .His company is employed by dozens of pharmaceutical companies and he is a consultant to a number of companies also .", "label": "", "metadata": {}, "score": "68.15961"}
{"text": "CPRS - R : .Short Form : Conners ' Parent Rating Scale - Revised .dMPH : . dexmethylphenidate .DSM - IV - TR Diagnostic and Statistical Manual of Mental Disorders : .", "label": "", "metadata": {}, "score": "68.224625"}
{"text": "View Article .Conners CK , Sitarenios G , Parker JDA , Epstein JN : The Revised Conners ' Parent Rating Scale ( CPRS - R ) : factor structure , reliability , and criterion validity .", "label": "", "metadata": {}, "score": "68.392624"}
{"text": "KC Publishing , Irvine ; 1992 .p. 184 .Kaufman J , Birmaher B , Brent D , Rao U , Flynn C , Moreci P , Williamson D , Ryan N. Schedule for affective disorders and schizophrenia for school - age children - present and lifetime version ( K - SADS - PL ) : initial reliability and validity data .", "label": "", "metadata": {}, "score": "68.497574"}
{"text": "Dunnett test for multiple mean comparisons with least - squares adjustment was used to compare change from baseline in the 3 active treatment groups versus placebo .", "label": "", "metadata": {}, "score": "68.522545"}
{"text": "Study Design .This 8-week , parallel - group , randomized , double - blind , placebo - controlled study was conducted at 22 centers in the United States between March 2008 and February 2009 .", "label": "", "metadata": {}, "score": "68.53688"}
{"text": "Goldstein H : Multilevel Statistical Models .London : Institute of Education , Multilevel Models Project ; 1999 .Steiner JF : Can we identify clinical predictors of medication adherence ... and should we ?", "label": "", "metadata": {}, "score": "68.58643"}
{"text": "For subjects receiving OROS MPH , decreases ( improvements ) from baseline in CAARS : O - SV score were numerically greater in subjects defined as adherent than in those who were not , in both the main analysis set and completer population ( Figure 3 ) .", "label": "", "metadata": {}, "score": "68.68636"}
{"text": "Safety and Tolerability .Full safety analyses have been reported previously [ 17 ] .In the safety population , 196/290 ( 68 % ) participants reported one or more TEAEs ; 21/290 ( 7.2 % ) discontinued due to TEAE .", "label": "", "metadata": {}, "score": "68.70224"}
{"text": "10.1001/jama.289.23.3095 .View Article PubMed .Wilens TE , Prince JB , Biederman J , Spencer TJ , Frances RJ : Attention - deficit hyperactivity disorder and comorbid substance use disorders in adults .", "label": "", "metadata": {}, "score": "68.82783"}
{"text": "For instance , compared to controls , differences have been identified in the binding potential of the dopamine transporter protein in adults with ADHD [ 11 - 13 ] .", "label": "", "metadata": {}, "score": "68.90851"}
{"text": "Differential responses to MPH and amphetamine may explain a successful clinical response to LDX in participants who had significant ADHD symptoms despite prior MPH therapy .", "label": "", "metadata": {}, "score": "68.941696"}
{"text": "Interventions .Treatment with atomoxetine .Main Outcome Measures .Treatment group differences ( atomoxetine vs placebo ) in terms of total score , domains , and subdomains of the CHIP - CE were compared across age groups , and correlations between ADHD - RS scores and CHIP - CE scores were calculated by age .", "label": "", "metadata": {}, "score": "68.9503"}
{"text": "Official Title : .A Phase 3 , Double - blind , Randomized , Multicenter , Placebo - controlled , Dose Optimization Study Evaluating the Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended - release Guanfacine Hydrochloride in Children Aged 6 - 12 With a Diagnosis of Attention - Deficit / Hyperactivity Disorder .", "label": "", "metadata": {}, "score": "68.95245"}
{"text": "Methods .Study design and subjects .LAMDA - II ( EudraCT # : 2007 - 002111 - 82 ) was a multicentre , double - blind , randomized , placebo - controlled , dose - response study conducted at 42 sites in Europe between February 2008 and April 2009 .", "label": "", "metadata": {}, "score": "68.96664"}
{"text": "Statistician BA has given final approval to this version .BS was the associate director , Scientific Publications , Clinical Development , and Medical Affairs for this study , and made substantial contributions to the analysis and interpretation of the data .", "label": "", "metadata": {}, "score": "69.05217"}
{"text": "Dr Lasser is an employee of Shire and holds stock and/or stock options in Shire .Authors ' contributions .RJ was an investigator on the parent study and participated in data acquisition , analysis , interpretation , and presentation .", "label": "", "metadata": {}, "score": "69.113556"}
{"text": "Results . 3.1 Patient disposition .Data from a total of 794 patients were included in the analysis .The age range was 6 to 15 years .", "label": "", "metadata": {}, "score": "69.133484"}
{"text": "At the end of the dose optimization period , 8.2 % , 27.2 % , and 52.2 % of treated patients were receiving Vyvanse doses of 30 , 50 , and 70 mg , respectively .", "label": "", "metadata": {}, "score": "69.14897"}
{"text": "View Article PubMed .Steele M , Weiss M , Swanson J , Wang J , Prinzo RS , Binder CE : A randomized , controlled effectiveness trial of OROS - methylphenidate compared to usual care with immediate - release methylphenidate in attention deficit - hyperactivity disorder .", "label": "", "metadata": {}, "score": "69.2527"}
{"text": "PBO indicates placebo .Alteration of stimulant medication dosage during the study .A greater percentage of patients in the CLON - XR plus stimulant group ( 15 % ) decreased their dose of stimulant compared with patients in the placebo plus stimulant group ( 10 % ) .", "label": "", "metadata": {}, "score": "69.25308"}
{"text": "Biol Psychiatry .10.1016/S0006 - 3223(02)01671 - 2 .View Article PubMed .Wesnes KA , McKeith I , Edgar C , Emre M , Lane R : Benefits of rivastigmine on attention in dementia associated with Parkinson disease .", "label": "", "metadata": {}, "score": "69.30838"}
{"text": "He has given final approval of this version .TBurtea was the medical director , Global Clinical Development and Medical Affairs for this study and made substantial contributions to the analysis , and interpretation of the data .", "label": "", "metadata": {}, "score": "69.335846"}
{"text": "10.1016/S0140 - 6736(99)04030 - 1 .View Article PubMed .Spencer TJ , Biederman J , Wilens TE : Efficacy and Tolerability of Long - Term , Open - Label , Mixed Amphetamine Salts Extended Release in Adolescents With ADHD .", "label": "", "metadata": {}, "score": "69.423935"}
{"text": "Patients who completed screening and washout periods were randomly assigned , via block design , to receive total daily doses of CLON - XR of 0.1 to 0.4 mg per day or placebo in addition to the patient 's normal regimen of stimulant .", "label": "", "metadata": {}, "score": "69.44996"}
{"text": "doi : 10.1016/j.jadohealth.2009.09.009 .[PubMed ] [ Cross Ref ] .Danckaerts M , Sonuga - Barke EJ , Banaschewski T , Buitelaar J , D\u00f6pfner M , Hollis C , Santosh P , Rothenberger A , Sergeant J , Steinhausen HC , Taylor E , Zuddas A , Coghill D. The quality of life of children with attention deficit / hyperactivity disorder : a systematic review .", "label": "", "metadata": {}, "score": "69.46773"}
{"text": "In the overall efficacy population , 169 ( 79.3 % ) treated with LDX and 21 ( 29.2 % ) treated with placebo achieved clinical response ( Figure 4 ) .", "label": "", "metadata": {}, "score": "69.49897"}
{"text": "At week 1 , patients were instructed to take 1 tablet of CLON - XR 0.1 mg or placebo at night in addition to their normal stimulant regimen .", "label": "", "metadata": {}, "score": "69.53934"}
{"text": "1996 , American Academy of Child and Adolescent Psychiatry , 121- .Spencer T , Biederman J , Wilens T , Faraone SV , Doyle RD , Surman C , Prince J , Mick E , Aleardi M , Herzig K : A large , double - blind , randomized clinical trial of methylphenidate in the treatment of adults with attention - deficit / hyperactivity disorder .", "label": "", "metadata": {}, "score": "69.54496"}
{"text": "Specifically , in the Risk Avoidance domain and in its two sub - domains ( IRA , TA ) , effect sizes indicated a more pronounced therapeutic effect of atomoxetine for adolescents compared with children ( see Table \u200b Table5 , 5 , \u200b , 6 6 and Figure \u200b Figure1 1 ) .", "label": "", "metadata": {}, "score": "69.56676"}
{"text": "A main strength of the present study is the size of the cohort , although it should be noted that this was a post - hoc analysis and the study was not designed to assess adherence .", "label": "", "metadata": {}, "score": "69.60169"}
{"text": "Eur Psychiatry 2012 , 27 : 321 - 328 .PubMed View Article .Tarter R , Hegedus A : The Drug Use Screening Inventory : its application in the evaluation and treatment of alcohol and drug abuse .", "label": "", "metadata": {}, "score": "69.62477"}
{"text": "View Article PubMed .Wilens T , Verlinden MH , Adler LA , Wozniak PA , West SA : ABT-089 , A Neuronal Nicotinic Receptor Partial Agonist , for the Treatment of Attention - Deficit / Hyperactivity Disorder in Adults : Results of a Pilot Study .", "label": "", "metadata": {}, "score": "69.65558"}
{"text": "[PubMed ] .Murphy K , Barkley RA .Prevalence of DSM - IV Symptoms of ADHD in adult licensed drivers : Implication for clinical diagnosis .", "label": "", "metadata": {}, "score": "69.8086"}
{"text": "10.1001/archpsyc.1978.01770280073008 .View Article PubMed .Elia J , Borcherding BG , Rapoport JL , Keysor CS : Methylphenidate and dextroamphetamine treatments of hyperactivity : are there true nonresponders ?", "label": "", "metadata": {}, "score": "69.85519"}
{"text": "PubMed View Article .Safren SA , Duran P , Yovel I , Perlman CA , Sprich S : Medication adherence in psychopharmacologically treated adults with ADHD .", "label": "", "metadata": {}, "score": "69.90799"}
{"text": "doi : 10.3111/200710091106 .[ Cross Ref ] .Svanborg P , Thernlund G , Gustafsson PA , H\u00e4ggl\u00f6f B , Poole L , Kadesj\u00f6 B. Efficacy and safety of atomoxetine as add - on to psychoeducation in the treatment of attention - deficit / hyperactivity disorder : a randomized , double - blind placebo controlled study in stimulant - na\u00efve Swedish children and adolescents .", "label": "", "metadata": {}, "score": "69.913895"}
{"text": "PubMed View Article .Pre - publication history .Copyright .\u00a9 Kooij et al . ; licensee BioMed Central Ltd. 2013 .This article is published under license to BioMed Central Ltd. 17 Jul 2014 Top - Line Results From Two Head - to - Head Studies Comparing Vyvanse \u00ae ( lisdexamfetamine dimesylate ) , CII , With Concerta \u00ae ( methylphenidate HCl ) , CII , in Adolescents with ADHD .", "label": "", "metadata": {}, "score": "69.957504"}
{"text": "10.1007/s00213 - 005 - 0164 - 7 .View Article .Rezvani AH , Levin ED : Cognitive effects of nicotine .Biol Psychiatry .", "label": "", "metadata": {}, "score": "70.0347"}
{"text": "An additional confounding effect could be that patients of the inattentive subtype typically have fewer ADHD symptoms and hence less severe ADHD and therefore benefit more by treatment .", "label": "", "metadata": {}, "score": "70.1781"}
{"text": "Polanczyk G , de Lima MS , Horta BL , Biederman J , Rohde LA .The worldwide prevalence of ADHD : a systematic review and metaregression analysis .", "label": "", "metadata": {}, "score": "70.22121"}
{"text": "The study was a multi - centre , double - blind , randomized placebo - controlled , parallel group design in outpatient adults ( 18 - 55 years ) testing 0.5 mg NS2359 vs. placebo for 8 weeks .", "label": "", "metadata": {}, "score": "70.309204"}
{"text": "By stimulating central alpha2A - adrenergic receptors , guanfacine reduces sympathetic nerve impulses from the vasomotor center to the heart and blood vessels .This results in a decrease in peripheral vascular resistance and a reduction in heart rate .", "label": "", "metadata": {}, "score": "70.58431"}
{"text": "Metabolism and Elimination .In vitro studies with human liver microsomes and recombinant CYP 's demonstrated that guanfacine was primarily metabolized by CYP3A4 .In pooled human hepatic microsomes , guanfacine did not inhibit the activities of the major cytochrome P450 isoenzymes ( CYP1A2 , CYP2C8 , CYP2C9 , CYP2C19 , CYP2D6 or CYP3A4/5 ) .", "label": "", "metadata": {}, "score": "70.59408"}
{"text": "To familiarize the patients with the tests and overcome training effects , each patient performed the entire battery on two occasions during the screening period .", "label": "", "metadata": {}, "score": "70.72687"}
{"text": "The analysis of change in CAARS : O - SV showed that lower adherence was significantly associated with less improvement in ADHD symptoms , particularly in subjects receiving OROS MPH .", "label": "", "metadata": {}, "score": "70.74174"}
{"text": "PubMed Central View Article PubMed .Wigal SB , Kollins SH , Childress AC , Squires L , for the 311 Study Group : A 13-hour laboratory school study of lisdexamfetamine dimesylate in school - aged children with attention - deficit / hyperactivity disorder .", "label": "", "metadata": {}, "score": "70.74719"}
{"text": "Adolescents were significantly more impaired at baseline in the Satisfaction with Self and the Family Involvement sub - domains as well as in the Achievement domain and the Academic Performance sub - domain .", "label": "", "metadata": {}, "score": "70.78511"}
{"text": "He has given final approval of this version .BA was a statistician involved in all post hoc data analysis , interpretation , and presentation .", "label": "", "metadata": {}, "score": "70.84984"}
{"text": "Authors ' contributions .PMW , AS , and RE developed the meta - analysis on which this manuscript is based .All Authors participated in interpreting the data .", "label": "", "metadata": {}, "score": "70.96466"}
{"text": "10.1007/s002130000533 .View Article .Seidman LJ : Neuropsychological functioning in people with ADHD across the lifespan .Clin Psychol Rev. 2006 , 26 : 466 - 485 .", "label": "", "metadata": {}, "score": "71.00719"}
{"text": "Patients were also excluded if they had a clinically significant illness or abnormality that would increase the safety risk of clonidine or if they had clinically significant electrocardiogram readings .", "label": "", "metadata": {}, "score": "71.015686"}
{"text": "It should also be noted that there are numerous possible methods of assessing adherence , including patient reports , carer reports , pill counts , pharmacy data , electronic measurement and measurement of plasma drug levels ; but none of these methods is ideal .", "label": "", "metadata": {}, "score": "71.018845"}
{"text": "The efficacy of CLON - XR monotherapy in children and adolescents with ADHD has been demonstrated in Phase 3 clinical trial data .An increasing rate of clonidine use in combination with psychostimulants for treating children and adolescents with ADHD has been documented in several studies , with a substantial proportion of stimulant - treated children also receiving clonidine .", "label": "", "metadata": {}, "score": "71.024536"}
{"text": "doi : 10.1176/appi.ajp.164.6.942 .[PubMed ] [ Cross Ref ] .Biederman J , Faraone SV , Spencer TJ , Mick E , Monuteaux MC , Aleardi M. Functional impairments in adults with self - reports of diagnosed ADHD :", "label": "", "metadata": {}, "score": "71.030426"}
{"text": "View Article PubMed .Faraone SV , Sergeant J , Gillberg C , Biederman J : The worldwide prevalence of ADHD : is it an American condition ?", "label": "", "metadata": {}, "score": "71.118546"}
{"text": "1999 , 13 : A26- .Biederman J , Spencer T : Non - stimulant treatments for ADHD .Eur Child Adolesc Psychiatry .2000 , 9 : I51 - 59 .", "label": "", "metadata": {}, "score": "71.177826"}
{"text": "J Am Acad Child Adolesc Psychiatry .View Article PubMed .Spencer T , Biederman J , Wilens T , Steingard R , Geist D : Nortriptyline treatment of children with attention - deficit hyperactivity disorder and tic disorder or Tourette 's syndrome .", "label": "", "metadata": {}, "score": "71.261284"}
{"text": "10.1016/j.biopsych.2004.11.043 .View Article PubMed .Wesnes KA , Ward T , McGinty A , Petrini O : The memory enhancing effects of a Ginkgo biloba / Panax ginseng combination in healthy middle - aged volunteers .", "label": "", "metadata": {}, "score": "71.3343"}
{"text": "View Article .Haynes RB , Ackloo E , Sahota N , McDonald HP , Yao X : Interventions for enhancing medication adherence .Cochrane Database Syst Rev 2008 , 2 : CD000011 .", "label": "", "metadata": {}, "score": "71.40875"}
{"text": "Results .NS2359 improved composite factor scores of attention , episodic- and working memory .No serious adverse events were reported with insomnia , headaches and loss of appetite most commonly reported as side effects .", "label": "", "metadata": {}, "score": "71.523094"}
{"text": "These combined scores have been used as outcome measures in a variety of studies [ 27 , 30 ] .There are two scores for attention , Power of Attention is the summation of the speed scores from the three attention tests ( Simple and choice reaction time , digit vigilance ) , and reflects the ability to focus attention .", "label": "", "metadata": {}, "score": "71.53815"}
{"text": "Participants receiving medication for ADHD at enrollment were allowed to continue their medication during the screening evaluation .After screening , the parents / caregivers of eligible participants were instructed to discontinue their prior ADHD medications , if they had not already done so .", "label": "", "metadata": {}, "score": "71.596436"}
{"text": "Although many people tend to think of ADHD as a childhood problem , 60 % to 85 % of children with ADHD may continue to meet the criteria for the disorder during their teenage years .", "label": "", "metadata": {}, "score": "71.65639"}
{"text": "Medication adherence has an important impact on treatment efficacy and healthcare burden across a range of conditions and therapeutic areas [ 1 ] .Indeed , improving adherence may have a greater impact on health than switching to a more potent or effective agent [ 2 ] .", "label": "", "metadata": {}, "score": "71.68628"}
{"text": "HR - QoL is a multidimensional concept that reflects the subjective physical , social , and psychological aspects of health , and goes beyond symptoms of the disorder and objective functional outcomes [ 11 ] .", "label": "", "metadata": {}, "score": "71.68828"}
{"text": "Overall , the authors concluded that further studies are needed to investigate the extent of the problems with adherence in adults with ADHD , particularly the impact of medication non - adherence on the symptoms of ADHD and related outcomes .", "label": "", "metadata": {}, "score": "71.80319"}
{"text": "The WFIRS - P is a 50-item scale with each item scored from 0 ( never / not at all ) to 3 ( very often / very much ) .", "label": "", "metadata": {}, "score": "71.86252"}
{"text": "The decrease in CAARS : O - SV was significantly larger for both MPH groups versus placebo .Again , both MPH groups showed a significantly larger improvement compared with placebo , and the decrease in CAARS : O - SV score over time was different between the treatment groups .", "label": "", "metadata": {}, "score": "71.89489"}
{"text": "J Clin Psychiatry .[PubMed ] .A prospective , multicenter , open - label assessment of atomoxetine in non - North American children and adolescents with ADHD .", "label": "", "metadata": {}, "score": "71.988464"}
{"text": "Curr Med Res Opin .doi : 10.1185/030079906X167309 .[PubMed ] [ Cross Ref ] .Wehmeier PM , Dittmann RW , Schacht A , Minarzyk A , Lehmann M , Sevecke K , Lehmkuhl G. Effectiveness of atomoxetine and quality of life in children with attention - deficit / hyperactivity disorder as perceived by patients , parents and physicians in an open - label study .", "label": "", "metadata": {}, "score": "72.00969"}
{"text": "View Article PubMed .Kessler RC , Berglund P , Demler O , Jin R , Koretz D , Merikangas KR , Rush AJ , Walters EE , Wang PS : The epidemiology of major depressive disorder : results from the National Comorbidity Survey Replication ( NCS - R ) .", "label": "", "metadata": {}, "score": "72.03756"}
{"text": "CNS stimulants ( amphetamines and methylphenidate - containing products ) have a high potential for abuse and dependence .Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy .", "label": "", "metadata": {}, "score": "72.17573"}
{"text": "LDX treatment was not associated with any significant changes in mean BP , ECG parameters , and laboratory values .Discussion .In this post hoc analysis , LDX showed efficacy when given to children with significant clinical ADHD symptoms despite prior MPH treatment .", "label": "", "metadata": {}, "score": "72.18211"}
{"text": "Michelson D , Adler L , Spencer T , Reimherr FW , West S , Allen AJ , Kelsey D , Wernicke J , Dietrich A , Milton D : Atomoxetine in adults with ADHD :", "label": "", "metadata": {}, "score": "72.18679"}
{"text": "10.1016/j.biopsych.2005.10.029 .View Article PubMed .Seibyl JP , Tabamo R , Jennings D , Tamagan G , Mikkelsen B , Marek K : NS2359 demonstrate dose - related dopamine and serotonin transporter occupancy in healthy male subjects with 123-l a - CIT SPECT imaging .", "label": "", "metadata": {}, "score": "72.236626"}
{"text": "Kooij JJ , Burger H , Boonstra AM , Van der Linden PD , Kalma LE , Buitelaar JK : Efficacy and safety of methylphenidate in 45 adults with attention - deficit / hyperactivity disorder : a randomized placebo - controlled double - blind cross - over trial .", "label": "", "metadata": {}, "score": "72.350174"}
{"text": "This Clinical Trials Network ( CTN ) study will evaluate the efficacy of osmotic - release methylphenidate ( OROS - MPH ) , relative to placebo , in treating ADHD and decreasing substance use in adolescents ( 13 - 18 years old ) with ADHD and a substance use disorder .", "label": "", "metadata": {}, "score": "72.48888"}
{"text": "Hence , measuring this construct is still a challenge , as are all measurements of subjectively perceived psychological constructs [ 6 ] . 4.2 Strengths .", "label": "", "metadata": {}, "score": "72.55681"}
{"text": "2011 , Wayne , PA : Shire US Inc .Pennick M : Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d - amphetamine .", "label": "", "metadata": {}, "score": "72.5594"}
{"text": "The most prominent treatment related an adverse effect reported was insomnia ( Table 2 ) .While there were more reported cases of weight reduction associated with study drug , there were no differences in rates of reported appetite suppression between groups .", "label": "", "metadata": {}, "score": "72.69389"}
{"text": "Fourteen ( 14 ) patients on Vyvanse , 3 patients on Concerta , and 3 patients on placebo had TEAEs that led to study discontinuation .", "label": "", "metadata": {}, "score": "72.717865"}
{"text": "Median age was 9 years and 11/26 ( 42.3 % ) female and 15/26 ( 57.7 % ) male participants were included .Table 1 .", "label": "", "metadata": {}, "score": "72.7205"}
{"text": "He has given final approval of this version .BD was the director , Clinical Development and Medical Affairs for this study , and made substantial contributions to the analysis and interpretation of the data .", "label": "", "metadata": {}, "score": "72.78955"}
{"text": "Methods .2.1 Subjects .Patients were recruited by advertisements in local media .Three sites in the US participated in the trial .The study was conducted according to the Declaration of Helsinki and was approved by independent ethics committee or institutional review board at each site .", "label": "", "metadata": {}, "score": "73.17619"}
{"text": "J Child Adolesc Psychopharmacol .doi : 10.1089/cap.2006.16.713 .[PubMed ] [ Cross Ref ] .Matza LS , Stoeckl MN , Shorr JM , Johnston JA .", "label": "", "metadata": {}, "score": "73.2144"}
{"text": "Thus , the safety and efficacy of CLON - XR plus stimulant in this patient population remain unknown .Second , the stimulant medication regimen in this study was allowed to vary on the basis of the response of individual patients to their specific regimen ( ie , methylphenidate or amphetamine ) .", "label": "", "metadata": {}, "score": "73.22919"}
{"text": "doi : 10.1007/s00787 - 008 - 0725 - 5 .[PubMed ] [ Cross Ref ] .Escobar R , Montoya A , Polavieja P , Cardo E , Artigas J , Hervas A , Fuentes J. Evaluation of patients ' and parents ' quality of life in a randomized placebo - controlled atomoxetine study in attention- deficit / hyperactivity disorder .", "label": "", "metadata": {}, "score": "73.33857"}
{"text": "NNT ( 95 % CI ) to achieve clinical response with LDX at treatment endpoint was 2.0 ( 1.21 , 6.63 ) in nonremitters on prior MPH , versus 1.8 ( 1.51 , 2.22 ) in the overall population .", "label": "", "metadata": {}, "score": "73.34117"}
{"text": "For example , adherence can be improved by simplifying medication regimens , particularly in terms of reduced frequency of dosing [ 1 , 4 , 5 ] .", "label": "", "metadata": {}, "score": "73.377205"}
{"text": "PubMed Central View Article PubMed .Behav Brain Funct .PubMed Central View Article PubMed .Biederman J , Krishnan S , Zhang Y , McGough JJ , Findling RL : Efficacy and tolerability of lisdexamfetamine dimesylate ( NRP-104 ) in children with attention - deficit / hyperactivity disorder : a phase III , multicenter , randomized , double - blind , forced - dose , parallel - group study .", "label": "", "metadata": {}, "score": "73.38078"}
{"text": "2006 , 13 : e50-e62 .PubMed .Banaschewski T , Coghill D , Santosh P , Zuddas A , Asherson P , Buitelaar J , Danckaerts M , Dopfner M , Faraone SV , Rothenberger A , Sergeant J , Steinhausen HC , Sonuga - Barke EJ , Taylor E : Long - acting medications for the hyperkinetic disorders .", "label": "", "metadata": {}, "score": "73.62233"}
{"text": "These changes include an increase in physical size and maturation , the desire to individuate from parents , resulting in more time spent away from home , an increase in the number of life activities to which the adolescent must adapt .", "label": "", "metadata": {}, "score": "73.62372"}
{"text": "In addition , analysis of covariance with terms for class of concomitant ADHD medication ( ie , methylphenidate or amphetamine ) was performed on subgroups .", "label": "", "metadata": {}, "score": "73.80876"}
{"text": "- existing psychiatric problems in ADHD in the ADORE cohort .Eur Child Adolesc Psychiatry .2006 ; 15 ( Suppl .[PubMed ] .", "label": "", "metadata": {}, "score": "73.82054"}
{"text": "Studies in Specific Populations .Renal Impairment .The impact of renal impairment on the pharmacokinetics of guanfacine in children was not assessed .In adult patients with impaired renal function , the cumulative urinary excretion of guanfacine and the renal clearance diminished as renal function decreased .", "label": "", "metadata": {}, "score": "73.91551"}
{"text": "Although it has previously been thought that ADHD is essentially a disorder of childhood , a growing body of literature suggests that the disorder persists through adolescence and into adulthood with some core features and associated impairments still evident [ 2 , 7 , 27 - 29 ] .", "label": "", "metadata": {}, "score": "73.92223"}
{"text": "Unfortunately , power to detect such interactions is generally low and further research is needed to obtain more information on treatment effect modifiers to ultimately tailor the medication to the individual patient .", "label": "", "metadata": {}, "score": "74.025566"}
{"text": "Daily adherence was calculated as average daily adherence ( 100 \u00d7 capsules taken/2 ) , with overall adherence calculated as the average daily adherence .Predictors of adherence were assessed using mixed - effects logistic regression .", "label": "", "metadata": {}, "score": "74.02643"}
{"text": "[PubMed ] .Wehmeier PM , Schacht A , Barkley RA .Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life .", "label": "", "metadata": {}, "score": "74.14043"}
{"text": "View Article PubMed .Barkley R : Major life activity and health outcomes associated with attention - deficit hyperactivity disorder .J Clin Psychiatry .PubMed .", "label": "", "metadata": {}, "score": "74.33221"}
{"text": "Specifically , hyperactive / impulsive symptoms show a definite decline over time , while inattentive symptoms may become even more pronounced during adolescence [ 3 , 29 - 32 ] .", "label": "", "metadata": {}, "score": "74.346954"}
{"text": "Prohibited treatments were stimulants within 1 week prior to randomization , benzodiazepines , anticonvulsants and lithium for 2 weeks , tricyclic , atypical , and selective serotonin reuptake inhibitor antidepressants within 4 weeks and antipsychotics and monoamine oxidase inhibitors for 8 weeks .", "label": "", "metadata": {}, "score": "74.47795"}
{"text": "Atomoxetine was effective in improving some aspects of HR - QoL in both age groups .Correlations between core symptoms of ADHD and HR - QoL were low to moderate .", "label": "", "metadata": {}, "score": "74.51104"}
{"text": "He has given final approval of this version .RL was the senior director , Clinical Development and Medical Affairs for this study , and made substantial contributions to the analysis and interpretation of the data .", "label": "", "metadata": {}, "score": "74.64577"}
{"text": "Concomitant stimulant medication was prescribed by the patient 's regular physician and was obtained from the patient 's usual pharmacy .Caregivers recorded the specific amount of CLON - XR and stimulant medication the patient received each week in a medication diary provided by the site personnel .", "label": "", "metadata": {}, "score": "74.64587"}
{"text": "In particular , the discontinuers in the MPH groups had a low adherence .In the patients who completed the trial , there was no difference in adherence between the treatment groups .", "label": "", "metadata": {}, "score": "74.712036"}
{"text": "Hence , the combined monoaminergic reuptake inhibition plus pro - cholinergic effects of NS2359 may be related to the aggregate evidence of improved cognitive functioning in the current study .", "label": "", "metadata": {}, "score": "74.7623"}
{"text": "Adverse Events ( AEs ) were by spontaneous report .Standard safety parameters including clinical laboratory tests of blood and urine as well as standard safety parameters ( vital signs at each visit , ECGs , physical examination ) were completed at various time points throughout the study .", "label": "", "metadata": {}, "score": "74.77873"}
{"text": "Selling or sharing Vyvanse may harm others and is illegal .Vyvanse is indicated for the treatment Attention - Deficit / Hyperactivity Disorder ( ADHD ) in patients 6 years and above .", "label": "", "metadata": {}, "score": "74.80646"}
{"text": "PubMed .Spencer T , Biederman J : Non - stimulant treatment for attention - deficit / hyperactivity disorder .J Attent Disord .2002 , 6 : S109-S119 .", "label": "", "metadata": {}, "score": "74.97995"}
{"text": "Medical Care . doi : 10.1097/00005650 - 199808000 - 00010 .[PubMed ] [ Cross Ref ] Clonidine Extended - Release Tablets as Add - on Therapy to Psychostimulants in Children and Adolescents With ADHD .", "label": "", "metadata": {}, "score": "75.01405"}
{"text": "The 159 questions are subdivided into 11 domains : drug and alcohol use frequency , substance use , behavior pattern , health status , psychiatric disorder , social competence , family system , school performance , work adjustment , peer relationship and leisure / recreation .", "label": "", "metadata": {}, "score": "75.0377"}
{"text": "View Article PubMed .Spencer T , Biederman J , Wilens T : Nonstimulant treatment of adult attention - deficit / hyperactivity disorder .Psychiatric Clinics of North America .", "label": "", "metadata": {}, "score": "75.051285"}
{"text": "Eur Neuropsychopharmacol .[PubMed ] .Dickson RA , Jackiewicz G , Khattak S ,Poster presented at the 27thAnnual Conference of the Canadian Academy of Child and Adolescent Psychiatry ( CACAP )", "label": "", "metadata": {}, "score": "75.31334"}
{"text": "The mean pharmacokinetic parameters in adults following the administration of INTUNIV \u00ae 1 mg once daily and immediate - release guanfacine 1 mg once daily are summarized in Table 15 .", "label": "", "metadata": {}, "score": "75.36458"}
{"text": "DuPaul GJ , Power TJ , Anastopoulos AD , Reid R : ADHD Rating Scale - IV : Checklists , Norms , and Clinical Interpretation .", "label": "", "metadata": {}, "score": "75.41171"}
{"text": "In studies in which systematic pharmacokinetic data were obtained , there was a strong inverse correlation between body weight and plasma guanfacine concentrations .Placebo .", "label": "", "metadata": {}, "score": "75.542694"}
{"text": "AP was an investigator in the LAMDA - II trial , and was involved in the interpretation of the data , and the drafting and reviewing of the manuscript .", "label": "", "metadata": {}, "score": "75.89026"}
{"text": "The intent - to - treat population included patients who had been randomized , had a baseline observation , and at least one postbaseline observation .", "label": "", "metadata": {}, "score": "75.93156"}
{"text": "Participants will also attend weekly CBT sessions ( approximately 1 hour in length ) targeting their drug use .Placebo Comparator : Methylphenidate ( Placebo ) .", "label": "", "metadata": {}, "score": "75.99231"}
{"text": "10.1016/0165 - 1781(91)90126-A. View Article PubMed .Newcorn JH , Sutton VK , Weiss MD , Sumner CR : Clinical responses to atomoxetine in attention - deficit / hyperactivity disorder : the Integrated Data Exploratory Analysis ( IDEA ) study .", "label": "", "metadata": {}, "score": "76.27466"}
{"text": "J Clin Psychiatry .PubMed .Secnik K , Swensen A , Lage MJ : Comorbidities and costs of adult patients diagnosed with attention - deficit hyperactivity disorder .", "label": "", "metadata": {}, "score": "76.2858"}
{"text": "Utrecht : Trimbos Institute ; 2005 .Sosial- og helsedirektoratet : Diagnosis and Treatment of Hyperkinetic Disorder / Attention Deficit Hyperactivity Disorder ( ADHD ) in Children , Adolescents and Adults [ in Norwegian ] .", "label": "", "metadata": {}, "score": "76.31764"}
{"text": "He has given final approval of this version .TBabcock was the associate director , Scientific Publications , Clinical Development , and Medical Affairs for this study , and made substantial contributions to the analysis and interpretation of the data .", "label": "", "metadata": {}, "score": "76.32242"}
{"text": "doi : 10.1089/cap.2008.0109 .[PubMed ] [ Cross Ref ] .Dell'Agnello G , Maschiatto D , Bravaccio C , Calamoneri F , Masi G , Curatolo P , Besana D , Mancini F , Rossi A , Poole L , Escobar R , Zuddas A. LYCY Study Group .", "label": "", "metadata": {}, "score": "76.351685"}
{"text": "View Article PubMed .Arnold LE : Methylphenidate vs. amphetamine : comparative review .J Atten Disord .View Article .Vyvanse Product Monograph : 2011 , Saint - Laurent , Qu\u00e9bec : Shire Canada Inc .", "label": "", "metadata": {}, "score": "76.654236"}
{"text": "Some people have had the following problems when taking stimulant medicines , such as Vyvanse : .Tell your doctor if you or your child has any heart problems , heart defects , high blood pressure , or a family history of these problems .", "label": "", "metadata": {}, "score": "76.676094"}
{"text": "The treatment options for ADHD include psychostimulants ( e.g. methylphenidate , mixed amphetamine salts ) or atomoxetine , which is a non - stimulant treatment option for ADHD [ 12 ] , both in combination with behavioral therapy [ 13 ] .", "label": "", "metadata": {}, "score": "76.72263"}
{"text": "Impaired self - esteem and sociability in adolescents is often the result .In adolescence , symptoms of inattention and impaired executive function ( EF ) generally have a greater impact on school functioning than the symptoms of hyperactivity and impulsivity .", "label": "", "metadata": {}, "score": "76.75284"}
{"text": "J Clin Psychiatry .doi : 10.4088/JCP.v67n0403 .[PubMed ] [ Cross Ref ] .Brassett - Harknett A , Butler N. Attention - deficit / hyperactivity disorder : an overview of the etiology and a review of the literature relating to the correlates and lifecourse outcomes for men and women .", "label": "", "metadata": {}, "score": "76.89995"}
{"text": "Abstract .Background .Attention - deficit / hyperactivity disorder ( ADHD ) is a common neurobehavioral psychiatric disorder that afflicts children , with a reported prevalence of 2.4 % to 19.8 % worldwide .", "label": "", "metadata": {}, "score": "76.91887"}
{"text": "OROS : . osmotic release oral system .RCT : . randomized controlled trial .SR : . sustained - release .TEAE : . treatment - emergent AE .", "label": "", "metadata": {}, "score": "76.940155"}
{"text": "The study protocol , amendments , and informed consent form were approved by central and local institutional review boards before study initiation .The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice requirements .", "label": "", "metadata": {}, "score": "76.94307"}
{"text": "The research protocol was approved by the ethics committees at each site ( Table 1 ) , and all participants gave written informed consent .Full details of the study design and eligibility criteria have been published previously [ 18 ] .", "label": "", "metadata": {}, "score": "77.12701"}
{"text": "One short - term , placebo - controlled adjunctive trial with psychostimulants ( Study 3 ) .Studies 1 and 2 : Fixed - dose INTUNIV \u00ae Monotherapy .", "label": "", "metadata": {}, "score": "77.148346"}
{"text": "Adult outpatients of either sex ( aged 18 - 55 inclusive ) who met DSM - IV criteria for Attention Deficit Hyperactivity Disorder [ 24 ] were entered into the study .", "label": "", "metadata": {}, "score": "77.28784"}
{"text": "Pediatrics .doi : 10.1542/peds.2004 - 1959 .[PubMed ] [ Cross Ref ] .Barkley RA .Major life activity and health outcomes associated with attention - deficit / hyperactivity disorder .", "label": "", "metadata": {}, "score": "77.33438"}
{"text": "The placebo estimate for responding in the ITT population was estimated to be 26.7 % , so the placebo assumption of 25 % , and hence the above sample size calculation , was justifiable .", "label": "", "metadata": {}, "score": "77.361534"}
{"text": "CNS Spectr .PubMed .Levin ED , McClernon FJ , Rezvani AH : Nicotinic effects on cognitive function : behavioral characterization , pharmacological specification , and anatomic localization .", "label": "", "metadata": {}, "score": "77.37018"}
{"text": "For example , the disorder is highly genetic , is lifelong , and is likely to interfere with completion of education .Furthermore , some of its symptoms may be mimicked by other psychiatric disorders ( e.g. anxiety or depression may produce difficulty concentrating or maintaining focus on current activities ) .", "label": "", "metadata": {}, "score": "77.48662"}
{"text": "Johnston C , Pelham WE , Hoza J , Sturges J : Psychostimulant rebound in attention deficit disordered boys .J Am Acad Child Adolesc Psychiatry 1988 , 27 : 806 - 810 .", "label": "", "metadata": {}, "score": "77.726"}
{"text": "Methods .In this post hoc analysis of data from a multicenter , randomized , double - blind , forced - dose titration study , we evaluated the clinical efficacy of LDX in children aged 6 - 12 years with and without prior MPH treatment at screening .", "label": "", "metadata": {}, "score": "77.84468"}
{"text": "The low dialysis clearance suggests that the hepatic elimination ( metabolism ) increases as renal function decreases .Hepatic Impairment .The impact of hepatic impairment on PK of guanfacine in children was not assessed .", "label": "", "metadata": {}, "score": "77.88215"}
{"text": "Furthermore , physicians and other healthcare workers should encourage good adherence by education of , and discussion with , the patient about all aspects involved in treatment , to maximize treatment efficacy .", "label": "", "metadata": {}, "score": "77.91611"}
{"text": "Call your doctor right away if you or your child has any new or worsening mental symptoms or problems while taking Vyvanse .Call your doctor right away if you have or your child has any of these signs or symptoms or develops unexplained wounds on fingers or toes while taking Vyvanse . slowing of growth ( height and weight ) in children .", "label": "", "metadata": {}, "score": "78.14427"}
{"text": "All patients received two capsules per day ( 1 \u00d7 18 mg + 1 \u00d7 36 mg , 2 \u00d7 36 mg or 2 \u00d7 placebo ) .", "label": "", "metadata": {}, "score": "78.22526"}
{"text": "DuPaul GJ , Power TJ , Anastopoulos AD , Reid R. ADHD Rating Scale - IV : checklists , norms , and clinical interpretations .New York : Guilford ; 1998 .", "label": "", "metadata": {}, "score": "78.2488"}
{"text": "Keywords .Attention - deficit / hyperactivity disorder ( ADHD ) lisdexamfetamine dimesylate ( LDX ) methylphenidate children efficacy .Electronic supplementary material .The online version of this article ( doi : 10 .", "label": "", "metadata": {}, "score": "78.42494"}
{"text": "View Article PubMed .Sprague RL , Sleator EK : Methylphenidate in hyperkinetic children : differences in dose effects on learning and social behavior .Science .", "label": "", "metadata": {}, "score": "78.47731"}
{"text": "Randomized Controlled Trial of Osmotic - Release Methylphenidate ( OROS - MPH ) for Attention Deficit Hyperactivity Disorder ( ADHD ) in Adolescents With Substance Use Disorders ( SUD ) .", "label": "", "metadata": {}, "score": "78.56911"}
{"text": "Claxton AJ , Cramer J , Pierce C : A systematic review of the associations between dose regimens and medication compliance .Clin Ther 2001 , 23 : 1296 - 1310 .", "label": "", "metadata": {}, "score": "78.62894"}
{"text": "One such mixed monoamine reuptake blocker is the novel agent NS2359 , which acts by equipotent reuptake blockade across the noradrenalin , dopamine and serotonin transporters .", "label": "", "metadata": {}, "score": "78.73254"}
{"text": "LDX treatment was administered in a forced - dose titration , while prior MPH therapy was provided according to community standards and included potential suboptimal dosing .", "label": "", "metadata": {}, "score": "78.76021"}
{"text": "Study 3 , which was carried out in Italy , did not explicitly require medication - na\u00efve patients , but at the time of recruitment , there were no ADHD drugs approved by authorities in that country . 2.2 Measures .", "label": "", "metadata": {}, "score": "78.83824"}
{"text": "Shire enables people with life - altering conditions to lead better lives .Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs .", "label": "", "metadata": {}, "score": "78.875595"}
{"text": "List of Abbreviations .CGI - S : .Clinical Global Impressions - Severity .CGI - I : .Clinical Global Impressions - Improvement .", "label": "", "metadata": {}, "score": "78.89444"}
{"text": "Formerly Janssen Medical Affairs Europe , Middle East & Africa ; now at UCB Pharma S.A .References .Bubalo J , Clark RK Jr , Jiing SS , Johnson NB , Miller KA , Clemens - Shipman CJ , Sweet AL : Medication adherence : pharmacist perspective .", "label": "", "metadata": {}, "score": "78.95332"}
{"text": "Conclusion .Despite the limitations presented above , these data show that the current dose of NS2359 is well tolerated but insufficient to treat ADHD adequately in the general population of adults with ADHD .", "label": "", "metadata": {}, "score": "78.96858"}
{"text": "Faculty Practice Offices NYU Medical Center .CNS Healthcare , MD .Cognitive Drug Research Ltd .References .Wilens T , Spencer T , Biederman J : A review of the pharmacotherapy of adults with attention - deficit / hyperactivity disorder .", "label": "", "metadata": {}, "score": "78.99122"}
{"text": "10.1023/A:1022602400621 .View Article PubMed .Guy W : Clinical global impressions .ECDEU Assessment Manual for Psychopharmacology .1976 , Rockville , MD : US Department of Health , Education , and Welfare ; Public Health Service , Alcohol , Drug Abuse and Mental Health Administration , NIMH Psychopharmacology Research Branch , 218 - 222 .", "label": "", "metadata": {}, "score": "79.169495"}
{"text": "Given the mixed findings in this group of subjects , larger , parallel design dose ranging studies with NS2359 using higher doses are warranted .Declarations .", "label": "", "metadata": {}, "score": "79.1836"}
{"text": "Moreover , regulatory approvals or interventions associated with changes to manufacturing sites , ingredients or manufacturing processes could lead to significant delays , increase in operating costs , lost product sales , an interruption of research activities or the delay of new product launches ; .", "label": "", "metadata": {}, "score": "79.21422"}
{"text": "Nearly two - thirds ( 64.2 % ) of patients reached optimal doses in the 0.05 - 0.12 mg / kg / day range .Studies 4 , 5 and 6 : Flexible - dose INTUNIV \u00ae Monotherapy .", "label": "", "metadata": {}, "score": "79.33478"}
{"text": "doi : 10.1177/108705479600100303 .[ Cross Ref ] .Kordon A , Kahl KG , Wahl K. A new understanding of attention - deficit disorders -- beyond the age - at - onset criterion of DSM - IV .", "label": "", "metadata": {}, "score": "79.34213"}
{"text": "The specific etiology of ADHD is unknown .The diagnosis is made utilizing criteria specified in the Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition , ( DSM-5 \u00ae ) or International Classification of Diseases , 10th revision ( ICD-10 ) .", "label": "", "metadata": {}, "score": "79.39706"}
{"text": "Clinical Global Impression - Improvement ( CGI - I ) consists of a 7-point scale ranging from 1 ( very much improved ) to 7 ( very much worse ) .", "label": "", "metadata": {}, "score": "79.521576"}
{"text": "^ The lowest dose of 1 mg used in Study 2 was not randomized to patients weighing more than 50 kg .Study 3 : Flexible - dose INTUNIV \u00ae as Adjunctive Therapy to Psychostimulants .", "label": "", "metadata": {}, "score": "79.54228"}
{"text": "JD carried out the statistical analyses and was involved in the interpretation of the data , and the drafting and reviewing of the manuscript .AvdK was involved in the interpretation of the data , and the drafting and reviewing of the manuscript .", "label": "", "metadata": {}, "score": "79.61532"}
{"text": "The data demonstrated that INTUNIV showed significant efficacy in reducing ADHD symptoms for patients taking the medication when compared to patients taking placebo at all measured time points up to 24 hours postdose .", "label": "", "metadata": {}, "score": "79.98743"}
{"text": "In the event such risks or uncertainties materialize , Shire 's results could be materially adversely affected .The risks and uncertainties include , but are not limited to , that : .", "label": "", "metadata": {}, "score": "80.00073"}
{"text": "doi : 10.1097/00004583 - 199707000 - 00021 .[PubMed ] [ Cross Ref ] .Guy W , ed .ECDEU assessment manual for psychopharmacology : publication ADM 76 - 338 .", "label": "", "metadata": {}, "score": "80.15507"}
{"text": "Furthermore , one important predictor of adherence - number of medication doses - could not be analysed in the present study , as all patients received a single daily dose of OROS MPH or placebo .", "label": "", "metadata": {}, "score": "80.17183"}
{"text": "No overall effect of NS2359 was found on overall symptoms of ADHD .There was also a modest signal of improvement in the inattentive adults with ADHD and cognition warranting further exploration using differing doses .", "label": "", "metadata": {}, "score": "80.21803"}
{"text": "The impact of short time since diagnosis on adherence may therefore reflect lower acceptance of the disorder and less motivation for treatment .Psychiatric comorbidity in patients with ADHD may lead to low adherence through impact of MPH on other symptoms , such as anxiety or depression , while substance abuse is clearly associated with non - attendance , stagnation of treatment and interference with evaluation of medication .", "label": "", "metadata": {}, "score": "80.3782"}
{"text": "Adler LD , Nierenberg AA : Review of medication adherence in children and adults with ADHD .Postgrad Med 2010 , 122 : 184 - 191 .", "label": "", "metadata": {}, "score": "80.418"}
{"text": "Post - hoc analysis of a 13-week randomized , double - blind placebo - controlled study of OROS methylphenidate ( MPH ) 54 and 72 mg / day .", "label": "", "metadata": {}, "score": "80.425674"}
{"text": "10.1001/archpsyc.62.10.1142 .View Article PubMed .Levin ED : Nicotinic receptor subtypes and cognitive function .J Neurobiol .10.1002/neu.10151 .View Article PubMed .", "label": "", "metadata": {}, "score": "80.63468"}
{"text": "CLINICAL PHARMACOLOGY .Mechanism Of Action .Guanfacine is a central alpha2A - adrenergic receptor agonist .Guanfacine is not a central nervous system ( CNS ) stimulant .", "label": "", "metadata": {}, "score": "80.70833"}
{"text": "The review also estimated that 87 % to 92 % participants respond to at least one of these stimulants .However , although MPH and amphetamine can effectively manage ADHD symptoms in most pediatric patients , many patients still fail to respond optimally to either .", "label": "", "metadata": {}, "score": "80.828636"}
{"text": "The doses evaluated in this study were Vyvanse 70 mg and Concerta 72 mg daily .Baseline ADHD - RS - IV total scores were 37.3 , 37.0 , and 36.1 for Vyvanse , Concerta , and placebo , respectively .", "label": "", "metadata": {}, "score": "80.8344"}
{"text": "Psychopharmacology ( Berl ) 2007 ; 194 ( 2):197 - 209 .doi : 10.1007/s00213 - 007 - 0840-x .[PubMed ] [ Cross Ref ] .", "label": "", "metadata": {}, "score": "80.843796"}
{"text": "Julius RJ , Novitsky MA Jr , Dubin WR : Medication adherence : a review of the literature and implications for clinical practice .J Psychiatr Pract 2009 , 15 : 34 - 44 .", "label": "", "metadata": {}, "score": "81.078354"}
{"text": "Overall , the AEs were mostly mild to moderate in severity .Adverse reactions that appeared to be dose - related in patients given INTUNIV included upper abdominal pain , constipation , dizziness , dry mouth , hypotension , sedation , and somnolence .", "label": "", "metadata": {}, "score": "81.10062"}
{"text": "JJSK has been a speaker for Janssen - Cilag BV , Shire and Eli Lilly BV , and has received unrestricted research grants from Janssen - Cilag BV and Shire .", "label": "", "metadata": {}, "score": "81.31711"}
{"text": "doi : 10.1016/j.cpr.2005.06.001 .[PubMed ] [ Cross Ref ] .Escobar R , Hervas A , Soutullo CA , Mardomingo MJ , Uru\u00f1uela A , Gilaberte I. Attention - deficit / hyperactivity disorder : burdens of the disease according to subtypes in recently diagnosed children .", "label": "", "metadata": {}, "score": "81.33446"}
{"text": "National Collaborating Centre for Mental Health : Attention Deficit Hyperactivity Disorder : Diagnosis and Management of ADHD in Children , Young People and Adults .London : National Institute for Health and Clinical Excellence ; 2009 .", "label": "", "metadata": {}, "score": "81.45038"}
{"text": "Med Care .doi : 10.1097/01 .mlr.0000114909.33878 .ca .[PubMed ] [ Cross Ref ] .Riley AW , Chan KS , Prasad S , Poole L. A global measure of child health - related quality of life : reliability and validity of the Child Health and Illness Profile - Child Edition ( CHIP - CE ) global score .", "label": "", "metadata": {}, "score": "81.49093"}
{"text": "View Article PubMed .J Am Acad Child Adolesc Psychiatry .chi.0000215326.51175 .eb .View Article PubMed .Heishman SJ , Henningfield JE : Discriminative stimulus effects of d - amphetamine , methylphenidate , and diazepam in humans .", "label": "", "metadata": {}, "score": "81.57486"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "81.64038"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "81.64038"}
{"text": "Saini SD , Schoenfeld P , Kaulback K , Dubinsky MC : Effect of medication dosing frequency on adherence in chronic diseases .Am J Manag Care 2009 , 15 : e22-e33 .", "label": "", "metadata": {}, "score": "81.70619"}
{"text": "Possible scores range from 0 to 54 , with higher scores indicating greater severity .Outcome is measured as the decrease in total severity score over time .", "label": "", "metadata": {}, "score": "81.96058"}
{"text": "Fluctuations in buying or distribution patterns by such customers can adversely impact Shire 's revenues , financial conditions or results of operations ; . investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire 's activities in the highly regulated markets in which it operates may result in the distraction of senior management , significant legal costs and the payment of substantial compensation or fines ; .", "label": "", "metadata": {}, "score": "81.99542"}
{"text": "Clonidine is an \u03b1 2 -adrenergic agonist that has been used to treat ADHD .9 , - , 16 A modified oral formulation of clonidine ( clonidine hydrochloride extended - release tablets ; CLON - XR ) ( KAPVAY ; Shionogi Inc , Florham Park , NJ ) was recently approved for treatment of ADHD .", "label": "", "metadata": {}, "score": "82.02191"}
{"text": "View Article PubMed .Association AP : Practice guidelines for the treatment of patients with substance use disorders : Alcohol , cocaine , opioids .Am J Psychiatry .", "label": "", "metadata": {}, "score": "82.04499"}
{"text": "Immediate - release guanfacine and INTUNIV \u00ae have different pharmacokinetic characteristics ; dose substitution on a milligram for milligram basis will result in differences in exposure .", "label": "", "metadata": {}, "score": "82.06639"}
{"text": "The US Food and Drug Administration ( FDA ) has approved a chewable tablet form of extended - release methylphenidate ( QuilliChew ER , Pfizer Inc ) for attention - deficit / hyperactivity disorder ( ADHD ) in children aged 6 years and older , the compa \" ... .", "label": "", "metadata": {}, "score": "82.0981"}
{"text": "Primary Psychiatry .Steinhausen HC , N\u00f8vick TS , Baldursson G , Curatolo P , Lorenzo MJ , Rodrigues Pereira R , Ralston SJ , Rothenberger A. ADORE Study Group .", "label": "", "metadata": {}, "score": "82.37481"}
{"text": "The dose was then maintained for a 3-week dose maintenance period before entry to 1 week of dose tapering .Patients took INTUNIV \u00ae either in the morning or the evening while maintaining their current dose of psychostimulant treatment given each morning .", "label": "", "metadata": {}, "score": "82.39846"}
{"text": "BS was involved in the interpretation of the data , and the drafting and reviewing of the manuscript .All authors read and approved the final manuscript .", "label": "", "metadata": {}, "score": "82.41734"}
{"text": "Clin Pediatr ( Phila ) 2006 ; 45 ( 9):819 - 827 .doi : 10.1177/0009922806294219 .[PubMed ] [ Cross Ref ] .Prasad S , Harpin V , Poole L , Zeitlin H , Jamdar S. Puvanendran on behalf of the SUNBEAM Study Group .", "label": "", "metadata": {}, "score": "82.45581"}
{"text": "PubMed View Article .CADDRA : Canadian ADHD Practice Guidelines .Toronto : Canadian Attention Deficit Hyperactivity Disorder Resource Alliance ; 2008 .BMC Psychiatry 2010 , 10 : 67 .", "label": "", "metadata": {}, "score": "82.508156"}
{"text": "10.1007/BF02244241 .View Article .Heal DJ , Cheetham SC , Smith SL : The neuropharmacology of ADHD drugs in vivo : insights on efficacy and safety .", "label": "", "metadata": {}, "score": "82.51047"}
{"text": "He has given final approval of this version .Authors ' Affiliations .Department of Psychiatry and Behavioral Sciences , University of Texas Medical School , Houston , Texas , and R / D Clinical Research , Inc .", "label": "", "metadata": {}, "score": "82.51453"}
{"text": "Pharmacodynamics .Guanfacine is a selective central alpha2A - adrenergic receptor agonist in that it has a 15 - 20 times higher affinity for this receptor subtype than for the alpha2B or alpha2C subtypes .", "label": "", "metadata": {}, "score": "82.72478"}
{"text": "In addition , the class of concomitant psychostimulant used was altered ( ie , changed from amphetamine to methylphenidate ) in 2 patients ( 1 per treatment group ) .", "label": "", "metadata": {}, "score": "82.749725"}
{"text": "AP is a consultant for Janssen - Cilag , Lilly , Medice , and Shire , and is a member of the speaker 's bureau of Janssen - Cilag , Medice , Shire , and Novartis .", "label": "", "metadata": {}, "score": "82.77644"}
{"text": "Based on previous findings that some patients fail to achieve optimal response to either MPH or amphetamine , children who were previously treated with MPH and continue to have ADHD symptoms may be responsive to amphetamine - based ADHD treatment .", "label": "", "metadata": {}, "score": "82.826645"}
{"text": "Furthermore , only one relatively low dose of NS2359 was studied that mostly likely underestimated the effect of the medication .One of the dilemmas of early phase studies is the determination of the optimal dose(s ) for a disorder .", "label": "", "metadata": {}, "score": "83.2079"}
{"text": "10.1097/CHI.0b013e31819c55b2 .View Article PubMed .Copyright .\u00a9 Jain et al ; licensee BioMed Central Ltd. 2011 .This article is published under license to BioMed Central Ltd. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms .", "label": "", "metadata": {}, "score": "83.37781"}
{"text": "The doctor may stop treatment if a problem is found during these check - ups . diarrhea . dizziness .dry mouth . irritability .loss of appetite .", "label": "", "metadata": {}, "score": "83.49657"}
{"text": "Speed of Memory is the summation of the speed scores from the two working memory tasks and the two recognition tasks , and reflects the time taken to retrieve information from memory .", "label": "", "metadata": {}, "score": "83.51781"}
{"text": "ADDITIONAL IMPORTANT SAFETY INFORMATION .Do not take Vyvanse if you or your child : . is taking or has taken within the past 14 days an anti - depression medicine called a monoamine oxidase inhibitor or MAOI .", "label": "", "metadata": {}, "score": "83.5989"}
{"text": "Guanfacine was not shown to prolong the QTc interval to any clinically relevant extent .Pharmacokinetics .Absorption and Distribution .Guanfacine is readily absorbed and approximately 70 % bound to plasma proteins independent of drug concentration .", "label": "", "metadata": {}, "score": "83.70189"}
{"text": "The CGI - Severity ( CGI - S ) assessment was conducted at the baseline visit and the CGI - Improvement ( CGI - I ) assessment was conducted at subsequent visits .", "label": "", "metadata": {}, "score": "83.96131"}
{"text": "\" Prospectively designed head - to - head clinical trials provide important information to physicians , patients , caregivers , and payors to make informed choices .", "label": "", "metadata": {}, "score": "83.99859"}
{"text": "Psychiatric Clinics of North America .Edited by : Spencer T. 2004 , Philadelphia , P.A. : Saunders Press , 27 : 187 - 201 .", "label": "", "metadata": {}, "score": "84.28455"}
{"text": "Patients receiving INTUNIV \u00ae showed statistically significantly greater improvement on the ADHD - RS - IV total score compared with patients receiving placebo ( see Table 17 ) .", "label": "", "metadata": {}, "score": "84.380714"}
{"text": "Educational level was not associated with adherence , but adherence was negatively correlated with ADHD symptoms .According to several published guidelines , MPH is the treatment of choice for adults with ADHD [ 9 - 13 ] .", "label": "", "metadata": {}, "score": "84.90857"}
{"text": "Further evaluation of the efficacy and safety information is currently under way .ABOUT Vyvanse \u00ae ( lisdexamfetamine dimesylate )Information about Vyvanse .Vyvanse is a federally controlled substance ( CII ) because it can be abused or lead to dependence .", "label": "", "metadata": {}, "score": "84.95924"}
{"text": "Similarly , NS2359 has been shown to enhance the release of acetylcholine in the frontal cortex and hippocampus , an effect that may be relevant for attentional performance [ 20 , 21 ] .", "label": "", "metadata": {}, "score": "85.01251"}
{"text": "Expert Rev Pharmacoeconomics Outcomes Res .doi : 10.1586/14737167.6.4.379 .[PubMed ] [ Cross Ref ] .Brown RT , Perwien A , Faries DE , Kratochvil CJ , Vaughan BS .", "label": "", "metadata": {}, "score": "85.04601"}
{"text": "trouble sleeping .upper stomach pain .vomiting .weight loss .For additional safety information , click here for Prescribing Information and Medication Guide and discuss with your doctor .", "label": "", "metadata": {}, "score": "85.068726"}
{"text": "Each of the tasks is brief , lasting 1 - 2 minutes , and each test session took about 18 minutes for the patient to complete .", "label": "", "metadata": {}, "score": "85.07951"}
{"text": "Treatment - emergent AEs ( TEAEs ) were coded using the Medical Dictionary for Regulatory Activities version 7.1 [ 27 ] .TEAEs referred to events with onset after the first date of treatment and no later than 3 days following termination of treatment .", "label": "", "metadata": {}, "score": "85.09442"}
{"text": "The information is presented on the computer screen and the patient responds on all tasks using a response module containing two buttons , one marked ' NO ' and the other ' YES ' .", "label": "", "metadata": {}, "score": "85.21123"}
{"text": "Concepts of adherence are continuing to evolve , and the factors involved in adherence can be extended to a broader concept of ' concordance , ' as recently introduced by David Coghill ( J. J. S. Kooij ; personal communication ) .", "label": "", "metadata": {}, "score": "85.22374"}
{"text": "J Child Psychol Psychiatry .10.1111/j.1469 -7610.1989.tb00236.x .View Article PubMed .Breton JJ , Bergeron L , Valla JP , Berthiaume C , Gaudet N , Lambert J , St - Georges M , Houde L , Lepine S : Quebec child mental health survey : prevalence of DSM - III - R mental health disorders .", "label": "", "metadata": {}, "score": "85.37167"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT00264797 .Attention Deficit Disorder with Hyperactivity Substance - Related Disorders Attention Deficit and Disruptive Behavior Disorders Chemically - Induced Disorders Mental Disorders Mental Disorders Diagnosed in Childhood Methylphenidate Central Nervous System Agents Central Nervous System Stimulants .", "label": "", "metadata": {}, "score": "85.38345"}
{"text": "The osmotic release oral system ( OROS ) formulation was designed to deliver MPH in a controlled manner , allowing once - daily dosing in children , adolescents and adults [ 16 , 17 ] .", "label": "", "metadata": {}, "score": "85.38379"}
{"text": "Wellpartner .Allocation : Randomized Endpoint Classification : Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Caregiver , Investigator , Outcomes Assessor ) Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "85.43248"}
{"text": "The pharmacokinetics were affected by intake of food when a single dose of INTUNIV \u00ae 4 mg was administered with a high - fat breakfast .", "label": "", "metadata": {}, "score": "85.48294"}
{"text": "PubMed Central PubMed .Wilens T , Faraone SV , Biederman J : Attention - Deficit / Hyperactivity Disorder in Adults .Journal of the American Medical Association .", "label": "", "metadata": {}, "score": "85.74692"}
{"text": "doi : 10.1089/cap.2007.0025 .[PubMed ] [ Cross Ref ] .Wehmeier PM , Schacht A , Lehmann M , Dittmann RW , Silva SG , March JS .", "label": "", "metadata": {}, "score": "85.80529"}
{"text": "More than 95 % of TEAEs were mild or moderate in intensity and most began during the first week of treatment and abated over time [ 17 ] .", "label": "", "metadata": {}, "score": "85.96265"}
{"text": "10.1016/S0304 - 3940(00)01040 - 5 .View Article PubMed .Dougherty D , Bonab A , Spencer T , Rauch S , Madras B , Fischman A : Dopamine transporter density in patients with attention deficit hyperactivity disorder .", "label": "", "metadata": {}, "score": "85.982544"}
{"text": "J Clin Psychol .doi : 10.1002/jclp.1029 .[PubMed ] [ Cross Ref ] .Cheng JY , Chen RY , Ko JS , Ng EM .", "label": "", "metadata": {}, "score": "86.1423"}
{"text": "Attention - deficit / hyperactivity disorder ( ADHD ) is characterized by developmentally inappropriate levels of inattention , impulsivity , and hyperactivity .3 , - , 5 Stimulant medications ( ie , methylphenidate and amphetamine ) are often first - line therapies for ADHD , 6 but not all patients respond optimally to these medications .", "label": "", "metadata": {}, "score": "86.14598"}
{"text": "the failure to obtain and maintain reimbursement , or an adequate level of reimbursement , by third - party payors in a timely manner for Shire 's products may impact future revenues , financial condition and results of operations ; .", "label": "", "metadata": {}, "score": "86.21842"}
{"text": "LDX is converted , primarily in the blood , to l - lysine and therapeutically active d - amphetamine [ 14 ] .In Canada , the approved dosages range from 20 to 60 mg capsules for once daily oral administration and in the United States from 20 to 70 mg also once daily [ 12 , 13 ] .", "label": "", "metadata": {}, "score": "86.285965"}
{"text": "Shire is conducting additional clinical work which is designed to enhance the label .Upon approval , INTUNIV will be the first selective alpha-2A receptor agonist indicated for the treatment of ADHD that may provide an important treatment option for patients and physicians .", "label": "", "metadata": {}, "score": "86.73634"}
{"text": "Some of Shire 's products or ingredients are only available from a single approved source for manufacture .Any disruption to the supply chain for any of Shire 's products may result in the Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time .", "label": "", "metadata": {}, "score": "86.765816"}
{"text": "J Clin Psychopharmacol .doi : 10.1097/JCP.0b013e3181d21763 .[PubMed ] [ Cross Ref ] .Riley AW , Green BF , Forrest CB , Starfield B , Kang M , Ensminger ME .", "label": "", "metadata": {}, "score": "87.14424"}
{"text": "In a study in 66 adults receiving short - acting methylphenidate ( MPH ) , participants reported using their medication as prescribed only half of the time on average ( 14.5 of 30 days ) [ 7 ] .", "label": "", "metadata": {}, "score": "87.339966"}
{"text": "Declarations .Acknowledgements .The LAMDA - II study and post - hoc analyses were funded by Janssen - Cilag EMEA .Editorial assistance with the drafting and completion of the manuscript was provided by Daniel Booth ( Bioscript Stirling , London , UK ) and funded by Janssen - Cilag EMEA .", "label": "", "metadata": {}, "score": "87.45703"}
{"text": "The primary aim of the study was to investigate the efficacy and safety of NS2359 in DSM IV diagnosed adults with ADHD .The secondary aim was to evaluate the effects of NS2359 on cognitive function , particularly attention , working memory and episodic memory .", "label": "", "metadata": {}, "score": "87.637276"}
{"text": "The instructions are read to the patient for each task , and the test administrator then initiates each task and monitors the performance of the patient to ensure compliance with the instructions .", "label": "", "metadata": {}, "score": "87.76227"}
{"text": "View Article PubMed .Medical Dictionary for Regulatory Activities ( MedDRA ) , Version 7.1 .2009 , Northrop Gruman Corporation .Pediatrics .2001 , 107 : E105 - 10.1542/peds.107.6 .", "label": "", "metadata": {}, "score": "88.085556"}
{"text": "Call your doctor right away if you or your child has any signs of heart problems such as chest pain , shortness of breath , or fainting while taking Vyvanse .", "label": "", "metadata": {}, "score": "88.25614"}
{"text": "Atomoxetine in the treatment of children and adolescents with attention - deficit / hyperactivity disorder : a randomized , placebo - controlled , dose - response study .", "label": "", "metadata": {}, "score": "88.36743"}
{"text": "Background .Stimulants have long been used to treat ADHD symptoms .The stimulant types most commonly used in ADHD treatment are methylphenidate ( MPH ) and amphetamine .", "label": "", "metadata": {}, "score": "88.65321"}
{"text": "RE , NS and VH revised the manuscript for important intellectual content .All authors have read and approved the final version of the manuscript .", "label": "", "metadata": {}, "score": "88.6537"}
{"text": "The NS2359 compound improved all three of the domains of cognitive function assessed with the CDR .Power of Attention reflects the ability to focus attention and to rapidly process information , and the positive effects with NS2359 indicate that subjects were better able to direct their attention to ongoing tasks and to sustain concentration .", "label": "", "metadata": {}, "score": "89.3558"}
{"text": "Acknowledgements .Clinical research was funded by the sponsor , Shire Canada Inc.Under the direction of the authors , Kira Belkin and William Perlman , employees of Excerpta Medica , and Huda Ismail Abdullah , PhD , and Michael Pucci , PhD , employees of SCI Scientific Communications & Information ( SCI ) , provided writing assistance for this publication .", "label": "", "metadata": {}, "score": "89.81622"}
{"text": "Competing interests .The research was funded by Eli Lilly and Company .PMW , AS , RE , and NS are full - time employees and stakeholders of Eli Lilly .", "label": "", "metadata": {}, "score": "90.010086"}
{"text": "Clinical Studies .Efficacy of INTUNIV \u00ae in the treatment of ADHD was established in children and adolescents ( 6 to 17 years ) in : .", "label": "", "metadata": {}, "score": "90.555786"}
{"text": "[PubMed ] [ Cross Ref ] .Spencer T , Heiligenstein JH , Biederman J , Faries DE , Kratochvil CJ , Conners CK , Potter WZ .", "label": "", "metadata": {}, "score": "90.90689"}
{"text": "Dr Dirks is an employee of Shire and holds stock and/or stock options in Johnson & Johnson and Shire .Mr Adeyi is an employee of Shire and holds stock and/or stock options in Shire .", "label": "", "metadata": {}, "score": "91.386154"}
{"text": "This compound is an investigational once - daily medication which is being evaluated for the treatment of the symptoms of Attention Deficit Hy .WASHINGTON , May 7 -- Shire plc(LSE : SHP , Nasdaq : SHPGY ) , the global specialty biopharmaceutical company , presented today at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV , a selective alpha-2A - agonist .", "label": "", "metadata": {}, "score": "91.776505"}
{"text": "Robert Morgan from Shire Canada Inc. also reviewed and edited the manuscript for scientific accuracy .Shire Canada Inc. provided funding to Excerpta Medica and SCI for support in writing and editing this manuscript .", "label": "", "metadata": {}, "score": "92.23894"}
{"text": "Attention - Deficit / Hyperactivity Disorder is a neurobehavioral disorder that manifests as a persistent pattern of inattention and/or hyperactivity - impulsivity that interferes with functioning or development and is inconsistent with developmental level .", "label": "", "metadata": {}, "score": "92.276596"}
{"text": "FORWARD - LOOKING STATEMENTS - \" SAFE HARBOR \" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 .Statements included in this announcement that are not historical facts are forward - looking statements .", "label": "", "metadata": {}, "score": "92.44622"}
{"text": "10.1016/S0149 - 2918(07)80083-X. View Article PubMed .American Psychiatric Association : Attention - deficit and disruptive behavior disorders .Diagnostic and Statistical Manual of Mental Disorders DSM - IV - TR . 2000 , Washington , DC : American Psychiatric Association , 85 - 93 .", "label": "", "metadata": {}, "score": "92.48134"}
{"text": "2001 ; 108 ( 5):E83 .doi : 10.1542/peds.108.5 . e83 .[PubMed ] [ Cross Ref ] .Am J Psychiatry .", "label": "", "metadata": {}, "score": "92.79964"}
{"text": "AAN .2004 ,Poster 04.074.2006 .Copyright .\u00a9 Wilens et al ; licensee BioMed Central Ltd. 2008 .This article is published under license to BioMed Central Ltd.", "label": "", "metadata": {}, "score": "93.34299"}
{"text": "PubMed View Article .Janssen - Cilag Ltd : Concerta XL 18 mg-36 mg Prolonged Release Tablets .High Wycombe : Janssen - Cilag Ltd ; 2010 .", "label": "", "metadata": {}, "score": "94.30458"}
{"text": "Attention deficit - hyperactivity disorder ( ADHD ) is an increasingly recognized and heterogeneous disorder of unclear etiology [ 1 ] characterized by core symptoms of hyperactivity , inattentiveness , and impulsivity .", "label": "", "metadata": {}, "score": "94.330414"}
{"text": "Pediatrics .2004 ; 114 ( 1):e1 - 8 .doi : 10.1542/peds.114.1 . e1 .[PubMed ] [ Cross Ref ] .", "label": "", "metadata": {}, "score": "94.35501"}
{"text": "No other changes to the ANOVA models were made .The level of significance was set to 0.05 , and all tests were carried out as 2-sided .", "label": "", "metadata": {}, "score": "94.93597"}
{"text": "Arch Dis Child .2005 ; 90 ( 1):i2-i7 .doi : 10.1136/adc.2004.059006 .[ PMC free article ] [ PubMed ] [ Cross Ref ] .", "label": "", "metadata": {}, "score": "95.04061"}
{"text": "Shire faces intense competition for highly qualified personnel from other companies , academic institutions , government entities and other organizations .Shire is undergoing a corporate reorganization and the consequent uncertainty could adversely impact Shire 's ability to attract and/or retain the highly skilled personnel needed for Shire to meet its strategic objectives ; . failure to achieve Shire 's strategic objectives with respect to the acquisition of ViroPharma Incorporated may adversely affect Shire 's financial condition and results of operations ; . and other risks and uncertainties detailed from time to time in Shire 's filings with the U.S. Securities and Exchange Commission , including its most recent Annual Report on Form 10-K. Abstract .", "label": "", "metadata": {}, "score": "95.314644"}
{"text": "Birgit Ohrt Mikkelsen is an employee of NeuroSearch and owns NeuroSearch shares .Authors ' contributions .Authors ' Affiliations .Clinical Research Program in Pediatric Psychopharmacology , Massachusetts General Hospital & Harvard Medical School .", "label": "", "metadata": {}, "score": "95.37975"}
{"text": "Below are the links to the authors ' original submitted files for images .Competing interests .Dr Babcock is an employee of Shire and holds stock and/or stock options in Shire .", "label": "", "metadata": {}, "score": "95.530754"}
{"text": "MPH is a catecholamine reuptake inhibitor , whereas amphetamines have additional presynaptic activity .Although MPH and amphetamine can effectively manage ADHD symptoms in most pediatric patients , many still fail to respond optimally to either .", "label": "", "metadata": {}, "score": "95.550705"}
{"text": "The online version of this article ( doi : 10 .1186/\u200b1744 - 9081 - 4 - 24 ) contains supplementary material , which is available to authorized users .", "label": "", "metadata": {}, "score": "95.565475"}
{"text": "doi : 10.1007/s00787 - 004 - 0401 - 3 .[PubMed ] [ Cross Ref ] .Perwien AR , Faries DE , Kratochvil CJ , Sumner CR , Kelsey DK , Allen AJ .", "label": "", "metadata": {}, "score": "96.72124"}
{"text": "( Date:2/11/2016 ) ...PORTLAND , Ore. , Feb. 11 , 2016 ... to announce the acquisition of SolutionsRx , a full - service 340B ... hospitals .", "label": "", "metadata": {}, "score": "97.07599"}
{"text": "( Date:2/11/2016 ) ... Feb. 11 , 2016 NOIT \u2122 Research LLC , a private , ... of Change \" campaign to assist needy families in obtaining ... unit sold between February 10 , 2016 and March 31 , ... needy family .", "label": "", "metadata": {}, "score": "98.71268"}
{"text": "NS2359 is a potent reuptake blocker of noradrenalin , dopamine , and serotonin .The aim of the study was to investigate the efficacy , safety and cognitive function of NS2359 in adults with a DSM IV diagnosis of ADHD .", "label": "", "metadata": {}, "score": "98.739784"}
{"text": "( Date:2/12/2016 ) ... ...February 12 , 2016 , ... ... at Zuckerberg San Francisco General Hospital on April 5 - 7 .The series is a ... create new habits .", "label": "", "metadata": {}, "score": "99.16487"}
{"text": "Moreover , the slow entrance of NS2359 into the human brain makes it a candidate for the treatment of ADHD with minimal potential for abuse .", "label": "", "metadata": {}, "score": "99.618744"}
{"text": "Although both are considered efficacious , a meta - analysis of 23 studies comparing the efficacy of immediate - release ( IR ) formulations of MPH and amphetamine in the treatment of children with ADHD revealed small but statistically significant differences in favor of amphetamine [ 10 ] .", "label": "", "metadata": {}, "score": "99.89113"}
{"text": "Saarland University Hospital , Neurocentre .Department of Psychiatry , University Hospital .Janssen Medical Affairs Europe , Middle East & Africa .SGS Life Science Services .", "label": "", "metadata": {}, "score": "100.663315"}
{"text": "PubMed Central PubMed .American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders DSM - IV .1994 , Washington , DC : American Psychiatric Association .", "label": "", "metadata": {}, "score": "100.69452"}
{"text": "Authors ' original submitted files for images .Below are the links to the authors ' original submitted files for images .Competing interests .Dr. Timothy Wilens receives grant support from , is a speaker for , or is a consultant for the following sources : Abbott , McNeil , Lilly , NIH ( NIDA ) , Merck , Novartis , Cephalon and Shire .", "label": "", "metadata": {}, "score": "100.7892"}
{"text": "J Dev Behav Pediatr .doi : 10.1097/00004703 - 200408000 - 00006 .[PubMed ] [ Cross Ref ] .Perwien AR , Kratochvil CJ , Faries DE , Vaughan BS , Spencer T , Brown RT .", "label": "", "metadata": {}, "score": "101.32434"}
{"text": "doi : 10.1037/0021 - 843X.111.2.279 .[PubMed ] [ Cross Ref ] .Br J Psychiatry .doi : 10.1192/bjp.bp.106.034389 .[PubMed ] [ Cross Ref ] .", "label": "", "metadata": {}, "score": "101.38088"}
{"text": "[PubMed ] .Kelsey DK , Sumner CR , Casat CD , Coury DL , Quintana H , Saylor KE , Sutton VK , Gonzales J , Malcolm SK , Schuh KJ , Allen AJ .", "label": "", "metadata": {}, "score": "101.4596"}
{"text": "Ethik - Kommission der Bayerischen Landes\u00e4rztekammer .Medizinische Ethik - Kommission II der Fakult\u00e4t f\u00fcr Klinische Medizin , Mannheim der Ruprecht - Karls - Universit\u00e4t Heidelberg .", "label": "", "metadata": {}, "score": "101.47438"}
{"text": "Accepted February 7 , 2011 .Address correspondence to Scott H. Kollins , PhD , Duke ADHD Program , 718 Rutherford Street , Durham , NC 27705 .", "label": "", "metadata": {}, "score": "101.569"}
{"text": "doi : 10.1007/s11126 - 008 - 9070 - 6 .[PubMed ] [ Cross Ref ] .Wallander JL , Schmitt M , Koot HM .", "label": "", "metadata": {}, "score": "101.582214"}
{"text": "doi : 10.1007/s00787 - 009 - 0046 - 3 .[ PMC free article ] [ PubMed ] [ Cross Ref ] .Harpin VA .", "label": "", "metadata": {}, "score": "102.194405"}
{"text": "Attention deficit / hyperactivity disorder ( ADHD ) is one of the most frequently diagnosed psychiatric disorders in childhood , characterized by 3 core symptoms : inattentiveness , hyperactivity , and impulsivity .", "label": "", "metadata": {}, "score": "103.68991"}
{"text": "2006 ; 15 ( Suppl1):138 - 145 .[PubMed ] .Hakkaart - van Roijen L , Zwirs BWC , Bouwmans C , Tan SS , Schulpen TW , Vlasveld L , Buitelaar JK .", "label": "", "metadata": {}, "score": "107.18054"}
{"text": "Beth Shier , ... .( Date:2/11/2016 ) ... , Feb. 11 , 2016 AAIPharma ... provider of custom manufacturing and development services for ... sterile fill - finish capabilities and capacity in its ... in demand has driven several recent investments . ...", "label": "", "metadata": {}, "score": "109.9455"}
{"text": "2006 ; 256 ( 1):i47 - 54 .doi : 10.1007/s00406 - 006 - 1007 - 1 .[PubMed ] [ Cross Ref ] .", "label": "", "metadata": {}, "score": "110.02573"}
{"text": "As in years ... .( Date:2/12/2016 ) ... ... , ... Coco Libre , the maker of coconut water beverages with a purpose , ... Event .", "label": "", "metadata": {}, "score": "111.41178"}
{"text": "( Date:2/12/2016 ) ... ...12 , 2016 , ...Each year , the American Physical Therapy Association ( APTA ) offers ... the Anaheim Convention Center .", "label": "", "metadata": {}, "score": "111.44008"}
{"text": "Baltimore , MD : The Johns Hopkins University ; 2001 .Riley AW , Forrest CB , Starfield B , Rebok GW , Robertson JA , Green BF .", "label": "", "metadata": {}, "score": "120.03744"}
{"text": "( Date:2/12/2016 ) ... ...12 , 2016 , ... CDRH Enforcement Trends : , Back to the Future , Feb. 25 , 2016 ... Winston Churchill said , \" Those who do n't learn from history are doomed to repeat it . \" , ... come knocking this year .", "label": "", "metadata": {}, "score": "123.09691"}
